<SEC-DOCUMENT>0001372514-23-000097.txt : 20230606
<SEC-HEADER>0001372514-23-000097.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230606165221
ACCESSION NUMBER:		0001372514-23-000097
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230602
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		23996737

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20230602.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:f796ffe8-0968-4b06-824b-cd8ddbf679af,g:827eae95-d350-4afc-a6a2-d753c070e75d,d:3c331911404649acb33c57c1812f97bb--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230602</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV8yLTEtMS0xLTQxNDgx_9706388e-1fbb-4171-b38d-c934fb99b890">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV8zLTEtMS0xLTQxNDgx_c8bfa458-b23b-4770-8b2d-9a3526fa217b">false</ix:nonNumeric><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV81LTEtMS0xLTQxODY2_df855593-0f56-4c07-996c-12954cf6f638">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230602.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-02</xbrli:startDate><xbrli:endDate>2023-06-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3c331911404649acb33c57c1812f97bb_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA2_07842d17-1475-4c91-97a1-a8b498638954">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8yMjM_e9ebf55a-f465-41d5-83cc-9e261a831de7">June 2, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzAx_d338e59d-6d69-4f0d-9fa9-b27674a4821f">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzEx_1099fa65-df92-4762-9d81-5cf081b33fbb">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NjY5ZDhlZDQyN2Q3NGUzNjkwODIwMDY0NmM0OGM0NDMvdGFibGVyYW5nZTo2NjlkOGVkNDI3ZDc0ZTM2OTA4MjAwNjQ2YzQ4YzQ0M18wLTAtMS0xLTQxNDgx_8e76007b-553b-4ca2-a601-776e454b536c">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NjY5ZDhlZDQyN2Q3NGUzNjkwODIwMDY0NmM0OGM0NDMvdGFibGVyYW5nZTo2NjlkOGVkNDI3ZDc0ZTM2OTA4MjAwNjQ2YzQ4YzQ0M18wLTEtMS0xLTQxNDgx_66585429-6644-454c-b447-b1d494c9c7b6">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzEy_b9ca2e7b-5466-4e70-8ff0-bf179f174265">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzE0_0f07b230-6f87-4dd7-807d-ab00195e3692">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzAz_b69d8c41-7745-4ccb-be1a-d5b09feb3a2a">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA0_81491789-28c9-478f-8edc-37ab6842f82b">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV80MTQ_b48c3f8c-ea9e-433b-aaf6-b3648eedd8b8">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV80MTg_895298ec-0936-4376-9f18-6aab32765d33">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA5_a9484b7c-44c5-4414-aed2-0f155cbb285a">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV8wLTAtMS0xLTQxNDgx_48b9eff7-345c-49d3-ae04-eeebb55160ad">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV8yLTAtMS0xLTQxNDgx_be16e4c4-ef07-4f61-8754-eda57a83b4ff">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV80LTAtMS0xLTQxNDgx_36f6d5e8-a6c6-4070-91ad-32f8240aecf0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV82LTAtMS0xLTQxNDgx_3163448f-77c1-452b-93d9-fd5179622e4b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTAtMS0xLTQxNDgx_755fd0fc-0fcc-49c7-97a9-16b7a0650972">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTItMS0xLTQxNDgx_d8a43bae-4a50-4c07-8fe5-d331d99e3d84">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTQtMS0xLTQxNDgx_b6331edb-bb13-4a4e-ace2-395285bf88d1">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA1_1983f948-ba73-42d3-8ba2-88df07bc5f72">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMDk5NTExNjI5MDk2_1983f948-ba73-42d3-8ba2-88df07bc5f72">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3c331911404649acb33c57c1812f97bb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.01.&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2023, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as underwriter (the &#8220;Underwriter&#8221;), pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the &#8220;Public Offering&#8221;), (i) 1,447,628 shares of common stock (the &#8220;Common Shares&#8221;), (ii) 3,908 shares of Series F Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;) convertible into up to 3,552,372 shares of common stock, (iii) Class C Warrants (the &#8220;Class C Warrants&#8221;) to purchase up to 5,000,000 shares of common stock, and (iv) Class D Warrants (the &#8220;Class D Warrants&#8221; and, together with the Class C Warrants, the &#8220;Warrants&#8221;) to purchase up to 5,000,000 shares of common stock, priced at a public offering price of $1.10 per Common Share, Class C Warrant and Class D Warrant or $999.90 per Preferred Share, 909 Class C Warrants and 909 Class D Warrants.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option (the &#8220;Overallotment Option&#8221;) to purchase up to (i) 750,000 additional Common Shares, (ii) 750,000 additional Class C Warrants and/or (iii) 750,000 additional Class D Warrants, solely to cover over-allotments. The Underwriter fully exercised the Overallotment Option on June 5, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The securities were offered by the Company pursuant to the Registration Statement on Form S-1 (File No. 333-271699), which was initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on May 5, 2023, amended on May 12, 2023 and June 1, 2023, and declared effective by the Commission on June 1, 2023 (the &#8220;Registration Statement&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, the Public Offering closed, and the Company issued and sold (i) 2,197,628 Common Shares (including 750,000 Common Shares sold pursuant to the exercise of the Overallotment Option), (ii) 3,908 Preferred Shares, (iii) 5,750,000 Class C Warrants (including 750,000 Class C Warrants sold pursuant to the exercise of the Overallotment Option), and (iv) 5,750,000 Class D Warrants (including 750,000 Class D Warrants sold pursuant to the exercise of the Overallotment Option). The net proceeds to the Company, after deducting the underwriting discount and commissions and estimated offering expenses payable by the Company, were approximately $5.6 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each Warrant is exercisable upon issuance at an initial exercise price per share of common stock of $1.10.   The Class C Warrants and the Class D Warrants will include a one-time reset of the exercise price to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average prices for the five (5) trading days immediately preceding the date that is sixty calendar days after issuance of the Class C Warrants and Class D Warrants. The Class C Warrants will expire on the five-year anniversary of their issuance, and the Class D Warrants will expire on the one-year anniversary of their issuance. The exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. Subject to limited exceptions, a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any Warrants, 9.99%) of the shares of common stock then outstanding. At the holder&#8217;s option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days&#8217; prior notice to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Underwriting Agreement contains representations, warranties and covenants made by the Company that are customary for transactions of this type. Under the terms of the Underwriting Agreement, the Company has agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended. In addition, pursuant to the terms of the Underwriting Agreement, the Company and its executive officers and directors have entered into lock-up agreements providing that the Company and each of these persons may not, without the prior written approval of the Underwriter, subject to limited exceptions, offer, sell, transfer or otherwise dispose of the Company&#8217;s securities for a period of 90 days following the date of the Underwriting Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, the Company entered into a warrant agency agreement with the Company&#8217;s transfer agent, VStock Transfer, LLC, which will also act as the warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the &#8220;Warrant Agency Agreement&#8221;).</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing summaries of the Underwriting Agreement, the Class C Warrants, the Class D Warrants and the Warrant Agency Agreement do not purport to be complete and are subject to, and qualified in their entirety by, such documents attached as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K (this &#8220;Current Report&#8221;), which are incorporated herein by reference. The Underwriting Agreement is attached hereto as an exhibit to provide interested persons with information regarding its terms but is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement as of specific dates indicated therein, were solely for the benefit of the parties to the Underwriting Agreement and may be subject to limitations agreed upon by the parties.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3c331911404649acb33c57c1812f97bb_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item5.03.&#160;&#160;&#160;&#160;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) with the Delaware Secretary of State. Each share of Series F Convertible Preferred Stock (the &#8220;Series F Preferred Stock&#8221;) is convertible into shares of the Company&#8217;s common stock at any time at the holder&#8217;s option. The holder, however, will be prohibited from converting shares Series F Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of the Company&#8217;s shares of common stock then issued and outstanding, which may be increased to 9.99% in certain circumstances. Shares of Series F Preferred Stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series F Preferred Stock will be required to (i) alter or change adversely the powers, preferences or rights given to the Series F Preferred Stock or alter or amend the Certificate of Designation, (ii) amend any provision of the Company&#8217;s certificate of incorporation that would have a materially adverse effect on the rights of the holders of the Series F Preferred Stock, (iii) increase the number of authorized shares of Series F Preferred Stock, or (iv) enter into any agreement with respect to the foregoing. Shares of Series F Preferred Stock will not be entitled to receive any dividends, unless and until specifically declared by the Company&#8217;s board of directors, and will rank:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">on parity with the Company&#8217;s common stock on an as-converted basis;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">on  parity with the Company&#8217;s Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series E Convertible Preferred Stock, none of which is outstanding, and Series D Convertible Preferred Stock, 7 shares of which are outstanding; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">senior to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms junior to the Series F Preferred Stock; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">on parity to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms on parity with the Series F Preferred Stock; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">junior to any class or series of the Company&#8217;s capital stock created thereafter specifically ranking by its terms senior to the Series F Preferred Stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the Certificate of Designation relating to the Series F Preferred Stock is filed as Exhibit 3.1 to this Current Report on Form 8-K. The foregoing summary of the terms of the Certificate of Designation is subject to, and qualified in its entirety by, such document, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3c331911404649acb33c57c1812f97bb_90"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01 Other Events.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2023, the Company issued a press release announcing that it had priced the Public Offering, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, the Company issued a press release announcing the closing of the Public Offering and the full exercise of the Overallotment Option, a copy of which is attached as Exhibit 99.2 to this Current Report and is incorporated herein by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is as inactive textual references only.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the closing of the Public Offering and giving effect to conversion notices received as of June 6, 2023 for the conversion of 2,331 Preferred Shares into 2,118,879 shares of common stock, the Company will have 6,340,777 shares of common stock outstanding.</span></div><div id="i3c331911404649acb33c57c1812f97bb_106"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit11-underwritingagre.htm">Underwriting Agreement dated as of June 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Ladenburg Thalmann &amp; Co. Inc.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-seriesfpreferred.htm">Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock </a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Class C Warrant (incorporated by reference to Exhibit 4.12 of Company&#8217;s Amendment No. 2 to the Registration Statement on Form S-1 filed on June 1, 2023 (File No. 333-271699))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Class D Warrant (incorporated by reference to Exhibit 4.13 of Company&#8217;s Amendment No. 2 to the Registration Statement on Form S-1 filed on June 1, 2023 (File No. 333-271699)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit43-warrantagencyagr.htm">Warrant Agency Agreement dated June </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit43-warrantagencyagr.htm">6,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit43-warrantagencyagr.htm"> 2023, by and between Kiora Pharmaceuticals, Inc. and VStock Transfer, LLC</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-pressreleasejun.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-pressreleasejun.htm">June 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-pressreleasejun.htm">, 2023</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992-closingpressrel.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992-closingpressrel.htm">June 6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992-closingpressrel.htm">, 2023</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3c331911404649acb33c57c1812f97bb_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: June 6, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit11-underwritingagre.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if7d4a49475dc4e09b618c47d8d572790_1"></div><div style="min-height:83.52pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit 1.1</font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1,447,628 SHARES OF COMMON STOCK,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3,908 SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> (CONVERTIBLE INTO 3,552,372 SHARES OF COMMON STOCK) AND</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5,000,000  CLASS C WARRANTS                                                               </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> (EXERCISABLE FOR 5,000,000 SHARES OF COMMON STOCK) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5,000,000  CLASS D WARRANTS                                                               </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> (EXERCISABLE FOR 5,000,000 SHARES OF COMMON STOCK) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">                      OF KIORA PHARMACEUTICALS, INC. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNDERWRITING AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>June 2, 2023</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ladenburg Thalmann &#38; Co. Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As the Representative of the</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Several underwriters, if any, named in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">640 Fifth Avenue, 4th Floor</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, New York 10019</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ladies and Gentlemen&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned, Kiora Pharmaceuticals, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Kiora Pharmaceuticals, Inc., the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby confirms its agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with the several underwriters (such underwriters, including the Representative (as defined below), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Underwriters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Underwriter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) named in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto for which Ladenburg Thalmann &#38; Co. Inc. is acting as representative to the several Underwriters (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is understood that the several Underwriters are to make a public offering of the Public Securities as soon as the Representative deems it advisable to do so.  The Public Securities are to be initially offered to the public at the public offering price set forth in the Prospectus. The Representative may from time to time thereafter change the public offering price and other selling terms.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is further understood that you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities and, if any, the Option Securities in accordance with this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to the terms defined elsewhere in this Agreement, (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Certificate of Designation (as defined below) and (b) the following terms have the meanings set forth in this Section 1.1&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 3.1(k).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with such Person as such terms are used in and construed under Rule 405 under the Securities Act.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the board of directors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Certificate of Designation to be filed prior to the Closing by the Company with the Secretary of State of Delaware in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Class C Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the shares of Common Stock issuable upon exercise of the Class C Warrants.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Class C Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with Section 2.1(a)(iii) and Section 2.2, which Class B Warrants shall be exercisable immediately upon issuance and have a term of exercise equal to five (5) years, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Class D Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the shares of Common Stock issuable upon exercise of the Class D Warrants.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Class D Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with Section 2.1(a)(iv) and Section 2.2, which Class D Warrants shall be exercisable immediately upon issuance and have a term of exercise equal to one (1) year, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the closing of the purchase and sale of the Closing Securities pursuant to Section 2.1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the hour and the date on the Trading Day on which all conditions precedent to (i) the Underwriters&#8217; obligations to pay the Closing Purchase </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Price and (ii) the Company&#8217;s obligations to deliver the Closing Securities, in each case, have been satisfied or waived, but in no event later than 10&#58;00 a.m. (New York City time) on the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) Trading Day following the date hereof or at such earlier time as shall be agreed upon by the Representative and the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Preferred Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(a)(ii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(b), which aggregate purchase price shall be net of the underwriting discounts and commissions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(a)(iii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(a)(i).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(a)(iii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Preferred Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means EisnerAmper LLP, with offices located at 733 Third Avenue, New York, NY 10017 and Haskell &#38; White LLP with offices located at 300 Spectrum Center Drive, Suite 300, Irvine, CA 92618.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Burns &#38; Levinson, LLP, with offices located at 125 High Street, Boston, MA 02110. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in the Certificate of Designation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in the Certificate of Designation.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 3.1(f).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EGS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Ellenoff Grossman &#38; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the date on which the parties execute and enter into this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exempt Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and&#47;or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.20(a) herein, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FINRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Financial Industry Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 3.1(i).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business&#59; and (c) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lock-Up Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the lock-up agreements that are delivered on the date hereof by each of the Company&#8217;s officers and directors, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(c).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2(c).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Closing Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2(b), which aggregate purchase price shall be net of the underwriting discounts and commissions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means up to 3,908 shares of the Company&#8217;s Series F Convertible Preferred Stock issued or issuable pursuant to Section 2.1(a)(ii) and having the rights, preferences and privileges set forth in the Certificate of Designation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock Agency Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the addendum to the Company&#8217;s Transfer Agency and Registrar Services Agreement with the Transfer Agent, pursuant to which the Transfer Agent agrees to act as transfer agent and conversion agent for the Preferred Stock, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preliminary Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, if any, any preliminary prospectus relating to the Securities included in the Registration Statement or filed with the Commission pursuant to Rule 424(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the final prospectus filed for the Registration Statement.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, if any, any supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Public Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Closing Securities and, if any, the Option Securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the various parts of the registration statement prepared by the Company on Form S-1 (File No. 333-271699) with respect to the Securities, each as amended as of the date hereof, including the Prospectus and Prospectus Supplement, if any, the Preliminary Prospectus, if any, and all exhibits filed with or incorporated by reference into such registration statement, and includes any Rule 462(b) Registration Statement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rule 424</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rule 462(b) Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any registration statement prepared by the Company registering additional Public Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 3.1(i).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Closing Securities, the Option Securities and the Underlying Shares.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section 2.1(a)(i) and Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a day on which the principal Trading Market is open for trading.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question&#58; the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Agreement, the Certificate of Designation, the Warrants, the Warrant Agency Agreement, the Preferred Stock Agency Agreement, the Lock-Up Agreements and any other documents or agreements executed in connection with the transactions contemplated hereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, with offices located at 18 Lafayette Place, Woodmere, New York 11598, and any successor transfer agent of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Underlying Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Conversion Shares and the Warrant Shares.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Agency Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the warrant agency agreement dated on or about the Closing Date, by and between the Company and VStock Transfer, LLC in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 2.1(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the shares of Common Stock issuable upon exercise of the Warrants.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Class C Warrants and Class D Warrants.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PURCHASE AND SALE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Upon the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate 1,447,628 shares of Common Stock, 3,908 shares of Preferred Stock, 5,000,000  Class C Warrants and 5,000,000 Class D Warrants, and each Underwriter agrees to purchase, severally and not jointly, at the Closing, the following securities of the Company&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the number of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth opposite the name of such Underwriter on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the number of shares of Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Preferred Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth opposite the name of such Underwriter on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Class C Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Class C Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Class A Warrants shall have an exercise price of $1.10, subject to adjustment as provided therein&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Class D Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Class D Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, collectively with the Closing Class C Warrants, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively with the Closing Shares and </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Closing Preferred Shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Class D Warrants shall have an exercise price of $1.10, subject to adjustment as provided therein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The combined purchase price for one Share, one Class C Warrant to purchase one Warrant Share and one Class D Warrant to purchase one Warrant Share shall be $1.012 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (for the avoidance of doubt, solely with respect to any Closing Securities sold to certain investors introduced by the Company included in Exhibit B to the March 2023 Engagement Agreement (as defined herein in Section 7.2), the Combined Purchase Price shall be $1.056) which shall be allocated as $0.9936 per Share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), $0.0092 per Class C Warrant and $0.0092 per Class D Warrant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The combined purchase price for one Closing Preferred Share, one Class C Warrant to purchase 909 Warrant Shares and one Class D Warrant to purchase 909 Warrant Shares shall be $919.908 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combined Preferred Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which shall be allocated as $903.1824 per Preferred Share, $8.3628 per Class C Warrant and $8.3628 per Class D Warrant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt"> On the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available funds equal to such Underwriter&#8217;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its respective Closing Securities and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at the Closing.  Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of EGS or such other location as the Company and Representative shall mutually agree. The Public Securities are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company acknowledges and agrees that, with respect to any Notice(s) of Conversion (as defined in the Certificate of Designation) delivered by a Holder (as defined in the Certificate of Designation) on or prior to 12&#58;00 p.m. (New York City time) on the Closing Date, which Notice(s) of Conversion may be delivered at any time after the time of execution of this Agreement, the Company shall deliver the Conversion Shares (as defined in the Certificate of Designation) subject to such notice(s) to the Holder by 4&#58;00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Share Delivery Date (as defined in the Certificate of Designation) under the Certificate of Designation.  The Company acknowledges and agrees that the Holders are third-party beneficiaries of this covenant of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Option to Purchase Additional Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">For the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative  is hereby granted an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to purchase, in the aggregate, up to 750,000 shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Class C Warrants to purchase up to 750,000 shares of Common Stock and Class D Warrants to purchase up to 750,000 shares of Common Stock and (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively with the Option Shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which may be purchased in any combination of Option Shares and&#47;or Option Warrants at the Share Purchase Price and&#47;or Warrant Purchase Price, respectively.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In connection with an exercise of the Option, (a) the purchase price to be paid for the Option Shares is equal to the product of the Share Purchase Price multiplied by the number of Option Shares to be purchased and (b) the purchase price to be paid for the Option Warrants is equal to the product of the Warrant Purchase Price multiplied by the number of Option Warrants to be purchased (the aggregate purchase price to be paid on an Option Closing Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Closing Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Option granted pursuant to this Section 2.2 may be exercised by the Representative as to all (at any time) or any part (from time to time) of the Option Securities within forty-five (45) days after the Execution Date.  An Underwriter will not be under any obligation to purchase any Option Securities prior to the exercise of the Option by the Representative.  Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail or electronic transmission setting forth the number of Option Shares and&#47;or Option Warrants to be purchased and the date and time for delivery of and payment for the Option Securities (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which will not be later than two (2) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of EGS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or at such other place (including remotely by other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Securities does not occur on the Closing Date, each Option Closing Date will be as set forth in the notice. Upon exercise of the Option, the Company will become obligated to convey to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will become obligated to purchase, the number of Option Shares and&#47;or Option Warrants specified in such notice.  The Representative may cancel the Option at any time prior to the expiration of the Option by written notice to the Company.  On each Option Closing Date, if any, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available funds equal to such Underwriter&#8217;s Option Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its respective Option Securities and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at the Option Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Option Closing shall occur at the offices of EGS or such other location as the Company and Representative shall mutually agree.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">At the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shares shall be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">At the Closing Date, the Closing Preferred Shares, which shares shall be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">At the Closing Date, the Closing Class C Warrants and, as to each Option Closing Date, if any, the applicable Option Warrants via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters&#59;</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">At the Closing Date, the Closing Class D Warrants and, as to each Option Closing Date, if any, the applicable Option Warrants via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">At the Closing Date, the Warrant Agency Agreement duly executed by the parties thereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">At the Closing Date, the Preferred Stock Agency Agreement duly executed by the parties thereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">At the Closing Date, evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of the State of Delaware&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">At the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance letter, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto and as to the Closing Date and as to each Option Closing Date, if any, a bring-down opinion including, without limitation, a negative assurance letter from Company Counsel in form and substance reasonably satisfactory to the Representative and the favorable opinions of intellectual property legal counsel and regulatory legal counsel to the Company, including, without limitation, a negative assurance letter, addressed to the Underwriters and in form and substance satisfactory to the Representative&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Contemporaneously herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all respects to the Representative from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down letter dated as of the Closing Date and each Option Closing Date, if any&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">At the Closing Date and on each Option Closing Date, the duly executed and delivered Officer&#8217;s Certificate, substantially in the form required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">At the Closing Date and on each Option Closing Date, the duly executed and delivered Secretary&#8217;s Certificate, substantially in the form required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Contemporaneously herewith, the duly executed and delivered Lock-Up Agreements.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Closing Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option Closing Date are subject to the following conditions being met&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company already qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the Company contained herein (unless as of a specific date therein)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">all obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been performed in all material respects&#59; </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">the delivery by the Company of the items set forth in Section 2.3 of this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">the Registration Statement shall be effective on the date of this Agreement and  at each of the Closing Date and each Option Closing Date, if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall have been instituted or shall, to the Company&#8217;s knowledge be pending or contemplated by the Commission and any request on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">by the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriters as described in the Registration Statement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">the Closing Shares, the Option Shares and the Underlying Shares have been approved for listing on the Trading Market&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">prior to and on each of the Closing Date and each Option Closing Date, if any&#58; (i)&#160;there shall have been no material adverse change or development involving a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement and Prospectus&#59; (ii)&#160;no action suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Affiliate of the Company before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income of the Company, except as set forth in the Registration Statement and Prospectus&#59; (iii)&#160;no stop order shall have been issued under the Securities Act with respect to the Registration Statement and no proceedings therefor shall have been initiated or threatened by the Commission&#59; and (iv)&#160;the Registration Statement and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the rules and regulations thereunder and shall conform in all material respects to the requirements of the Securities Act and the rules and regulations thereunder, and neither the Registration Statement nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company represents and warrants to the Underwriters as of the Execution Date, as of the Closing Date and as of each Option Closing Date, if any, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports.  The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subscribe for or purchase securities.  If the Company has no Subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Organization and Qualification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.  Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.  Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Authorization&#59; Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise to carry out its obligations hereunder and thereunder.  The execution and delivery of this Agreement and each of the other Transaction Documents by the Company, the filing of the Certificate of Designation with the Secretary of State of the State of Delaware and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals.  This Agreement and each other Transaction Document to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the filing of the Certificate of Designation with the Secretary of State of the State of Delaware, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected&#59; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Filings, Consents and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than&#58; (i) the filing with the Commission of the Prospectus and (ii) such filings as are required to be made under applicable state securities laws (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company has filed with the Commission the Registration Statement, including any related Prospectus or Prospectuses, for the registration of the Securities under the Securities Act, which Registration Statement has been prepared by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the Commission under the Securities Act.  The Registration Statement has been declared effective by the Commission on June 1, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Company has advised the Representative of all further information (financial and other) with respect to the Company required to be set forth therein in the Registration Statement and Prospectus Supplement.  Any reference in this Agreement to the Registration Statement, the Prospectus or the Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein&#59; and any reference in this Agreement to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Prospectus or the Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Prospectus or the Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included,&#8221; &#8220;described,&#8221; &#8220;referenced,&#8221; &#8220;set forth&#8221; or &#8220;stated&#8221; in the Registration Statement, the Prospectus or the Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Prospectus or the Prospectus Supplement, as the case may be.  No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus or the Prospectus Supplement has been issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company's knowledge, is threatened by the Commission. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">free writing prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Rule 405 under the Securities Act.   The Company will not, without the prior consent of the Representative, prepare, use or refer to, any free writing prospectus.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Issuance of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Securities are duly authorized, and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.  The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.  The holder of the Securities will not be subject to personal liability by reason of being such holders. The Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. All corporate action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken. The Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conform in all material respects to all statements with respect thereto contained in the Registration Statement.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The capitalization of the Company is as set forth in the SEC Reports.  The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and&#47;or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act.  No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.  Except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or the capital stock of any Subsidiary.  The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Underwriters). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  The authorized shares of the Company conform in all material respects to all statements relating thereto contained in the Registration Statement and the Prospectus. The offers and sales of the Company&#8217;s securities were at all relevant times either registered under the Securities Act and the applicable state securities or Blue Sky laws or, based in part on the representations and warranties of the purchasers, exempt from such registration requirements. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.  There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">SEC Reports&#59; Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. The agreements and documents described in the Registration Statement, the Prospectus, the Prospectus Supplement and the SEC Reports conform to the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the rules and regulations thereunder to be described in the Registration Statement, the Prospectus, the Prospectus Supplement or the SEC Reports or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected and (i)&#160;that is referred to in the Registration Statement, the Prospectus, the Prospectus Supplement or the SEC Reports, or (ii)&#160;is material to the Company&#8217;s business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&#8217;s knowledge, the other parties thereto, in accordance with its terms, except (x)&#160;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally, (y)&#160;as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z)&#160;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefore may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the best of the Company&#8217;s knowledge, any other party is in default thereunder and, to the best of the Company&#8217;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the best of the Company&#8217;s knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to environmental laws and regulations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Material Changes&#59; Undisclosed Events, Liabilities or Developments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans and (vi) no officer or director of the Company has resigned from any position with the Company.  The Company does not have pending before the Commission any request for confidential treatment of information.  Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. Unless otherwise disclosed in an SEC Report filed prior to the date hereof, the Company has not&#58; (i)&#160;issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money&#59; or (ii)&#160;declared or paid any dividend or made any other distribution on or in respect to its capital stock.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.  Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.  The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Labor Relations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">could reasonably be expected to result in a Material Adverse Effect.  None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good.  To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.  The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any Subsidiary&#58; (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.  The disclosures in the Registration Statement concerning the effects of Federal, State, local and all foreign regulation on the Company&#8217;s business as currently contemplated are correct in all material respects.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Title to Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties.  Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except where failure to be in compliance could not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to do so could have a Material Adverse Effect (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.  Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person.  To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights.  The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage.  Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Transactions With Affiliates and Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from, any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Sarbanes-Oxley&#59; Internal Accounting Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Subsidiaries are in compliance in all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereunder that are effective as of the date hereof and as of the Closing Date.  Subject to the material weaknesses identified in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that&#58; (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.  The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Evaluation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date.  Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt;text-decoration:underline">Certain Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in the Prospectus, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.  To the Company&#8217;s knowledge, there are no other arrangements, agreements or understandings of the Company or, to the Company&#8217;s knowledge, any of its stockholders that may affect the Underwriters&#8217; compensation, as determined by FINRA.  The Company has not made any direct or indirect payments (in cash, securities or otherwise) to&#58; (i)&#160;any person, as a finder&#8217;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company&#59; (ii)&#160; any FINRA member&#59; or (iii)&#160;any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve months prior to the Execution Date. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Investment Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended.  The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Listing and Maintenance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.  Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as disclosed in the SEC Reports, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees of the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt;text-decoration:underline">Application of Takeover Protections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling their obligations or exercising their rights under the Transaction Documents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disclosure&#59; 10b-5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, if any, at the time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable rules and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Preliminary Prospectus, Prospectus and the Prospectus Supplement, each as of its respective date, comply in all material respects with the Securities Act and the Exchange Act and the applicable rules and regulations. Each of the Preliminary Prospectus, Prospectus and the Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The SEC Reports, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (with respect to the SEC Reports incorporated by reference in the Preliminary Prospectus, Prospectus or Prospectus Supplement), in light of the circumstances under which they were made not misleading&#59; and any further documents so filed and incorporated by reference in the Preliminary Prospectus, Prospectus or Prospectus Supplement, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission.  There are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. There are no contracts or other documents required to be described in the Preliminary Prospectus, Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement, which have not been described or filed as required.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Integrated Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.  The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).  The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date.  The SEC Reports sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments.  Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt;text-decoration:underline">Tax Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required to be filed through the date hereof (taking into account any valid extensions), (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.  The provisions for taxes payable, </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements.  The term &#8220;taxes&#8221; mean all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of a similar kind of nature, together with any interest and any penalties, additions to tax, or additional amounts with respect thereto.  The term &#8220;returns&#8221; means all returns, declarations, reports, statements, and other documents required to be filed in respect to taxes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Foreign Corrupt Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.  The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material respects with the FCPA.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt;text-decoration:underline">Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the knowledge and belief of the Company, the Company Auditor (i) is an independent registered public accounting firm as required by the Exchange Act and (ii) only with respect to Haskell &#38; White LLP, shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending December 31, 2023.  The Company Auditor has not, during the periods covered by the financial statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and&#47;or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmaceutical Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and&#47;or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect.  There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect.  The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA.&#160; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt;text-decoration:underline">Stock Option Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated.  The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.71pt;text-decoration:underline">Office of Foreign Assets Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">U.S. Real Property Holding Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Representative&#8217;s request.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Bank Holding Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">BHCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Federal Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.  Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt;text-decoration:underline">Money Laundering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt;text-decoration:underline">D&#38;O Questionnaires</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the Company&#8217;s knowledge, all information contained in the questionnaires completed by each of the Company&#8217;s directors and officers immediately prior to the Offering and in the Lock-Up Agreement provided to the Underwriters is true and correct in all material respects and the Company has not become aware of any information which would cause the information disclosed in such questionnaires become inaccurate and incorrect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">FINRA Affiliation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the Company&#8217;s knowledge, no officer, director or any beneficial owner of 5% or more of the Company&#8217;s unregistered securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules and regulations of FINRA) that is participating in the Offering. The Company will advise the Representative and EGS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if it learns that any officer, director or owner of 5% or more of the Company&#8217;s outstanding shares of Common Stock or Common Stock Equivalents is or becomes an affiliate or associated person of a FINRA member firm. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt;text-decoration:underline">Officers&#8217; Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any certificate signed by any duly authorized officer of the Company and delivered to the Representative or EGS shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.37pt;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Board of Directors is comprised of the persons set forth under the heading of the Prospectus captioned &#8220;Management.&#8221; The qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of the Trading Market. At least one member of the Board of Directors qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and the rules of the Trading Market.  In addition, at least a majority of the persons serving on the Board of Directors qualify as &#8220;independent&#8221; as defined under the rules of the Trading Market.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Cybersecurity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IT Systems and Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data&#59; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individually or in the aggregate, have a Material Adverse Effect&#59; (iii)&#160;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data&#59; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses&#59; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.  </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OTHER AGREEMENTS OF THE PARTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendments to Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   The Company has delivered, or will as promptly as practicable deliver, or make available, to the Underwriters complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies of the Registration Statement (without exhibits), the Prospectus and the Prospectus Supplement, as amended or supplemented, in such quantities and at such places as an Underwriter reasonably requests.  Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material in connection with the offering and sale of the Securities other than the Prospectus, the Prospectus Supplement, the Registration Statement, and copies of the documents incorporated by reference therein. The Company shall not file any such amendment or supplement to which the Representative shall reasonably object in writing.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Federal Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its best efforts to comply with all requirements imposed upon it by the Securities Act and the rules and regulations thereunder and the Exchange Act and the rules and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales of or dealings in the Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating to the Securities is required to be delivered under the Securities Act, any event shall have occurred as a result of which, in the opinion of counsel for the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therein, in light of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply with the Securities Act, the Company will notify the Underwriters promptly and prepare and file with the Commission, subject to Section 4.1 hereof, an appropriate amendment or supplement in accordance with Section 10 of the Securities Act.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Filing of Final Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will file the Prospectus (in form and substance satisfactory to the Representative) with the Commission pursuant to the requirements of Rule 424.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Exchange Act Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of three years from the Execution Date, the Company will use its best efforts to maintain the registration of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock under the Exchange Act without the prior written consent of the Representative.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Free Writing Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company represents and agrees that it has not made and will not make any offer relating to the Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the rules and regulations under the Securities Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative is herein referred to as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; The Company represents that it will treat each Permitted Free Writing Prospectus as an &#8220;issuer free writing prospectus&#8221; as defined in rule and regulations under the Securities Act, and has complied and will comply with the applicable requirements of Rule 433 of the Securities Act, including timely Commission filing where required, legending and record keeping.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery to the Underwriters of Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will deliver to the Underwriters, without charge, from time to time during the period when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies of each Prospectus as the Underwriters may reasonably request.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Effectiveness and Events Requiring Notice to the Underwriters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will use its best efforts to cause the Registration Statement to remain effective with a current prospectus until the later of nine (9) months from the Execution Date and the date on which the Warrants are no longer outstanding, and will notify the Underwriters and holders of the Warrants immediately and confirm the notice in writing&#58; (i)&#160;of the effectiveness of the Registration Statement and any amendment thereto&#59; (ii)&#160;of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose&#59; (iii)&#160;of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose&#59; (iv)&#160;of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus, provided that the filing of an amendment or supplement to the Registration Statement on the SEC&#8217;s EDGAR system shall be deemed to be such notification&#59; (v)&#160;of the receipt of any comments or request for any additional information from the Commission&#59; and (vi)&#160;of the happening of any event during the period described in this Section 4.4 that, in the judgment of the Company, causes the Registration Statement or the Prospectus, as the case may be, to include an untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company will make every reasonable effort to obtain promptly the lifting of such order.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Review of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of five (5) years from the Execution Date, the Company, at its expense, shall cause its regularly engaged independent registered public accountants to review (but not audit) the Company&#8217;s financial statements for each of the first three fiscal quarters prior to the announcement of quarterly financial information.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Expenses of the Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">General Expenses Related to the Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby agrees to pay on each of the Closing Date and each Option Closing Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to&#58; (a) all filing fees and communication expenses relating to the registration of the Securities to be sold in the Offering (including the Option Securities) with the Commission&#59; (b) all FINRA Public Offering Filing System fees associated with the review of the Offering by FINRA&#59; (c) all fees and expenses relating to the listing of such Closing Shares, Option Shares and Underlying Shares on the Trading Market and such other stock exchanges as the Company and the Representative together determine&#59; (d) all fees, expenses and disbursements relating to the registration or qualification of such Securities under the &#8220;blue sky&#8221; securities laws of such states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation, all filing and registration fees, and the fees and expenses of Blue Sky counsel)&#59; (e) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&#8217; Agreement, Underwriters&#8217; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary&#59; (f) the costs and expenses of the Company&#8217;s public relations firm&#59; (g) the costs of preparing, printing and delivering the Securities&#59; (h) fees and expenses of the Transfer Agent for the Securities (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and fees and expenses pursuant to the Warrant Agency Agreement and the Preferred Stock Agency Agreement)&#59; (i) stock transfer and&#47;or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters&#59; (j) the fees and expenses of the Company&#8217;s accountants&#59; (k) the fees and expenses of the Company&#8217;s legal counsel and other agents and representatives&#59; (l) the Underwriters&#8217; costs of mailing prospectuses to prospective investors&#59; and (m) the costs associated with advertising the Offering in the national editions of the Wall Street Journal and New York Times after the Closing Date. The Underwriters may also deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or each Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Expenses of the Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date it will reimburse the Representative for its reasonable, out-of-pocket expenses incurred, including travel, databases, fees and disbursements of legal counsel, and of other consultants and advisors not to exceed $105,000 without the Company&#8217;s prior consent by deduction from the proceeds of the Offering contemplated herein.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Application of Net Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application described under the caption &#8220;Use of Proceeds&#8221; in the Prospectus.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery of Earnings Statements to Security Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will make generally available to its security holders as soon as practicable, but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement (which need not be certified by independent public or independent certified public accountants unless required by the Securities Act or the Rules and Regulations under the Securities Act, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Stabilization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative) has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Internal Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances that&#58; (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii)&#160;transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets&#59; (iii)&#160;access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; and (iv)&#160;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period of at least three years after the Execution Date.  The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">FINRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall advise the Underwriters (who shall make an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder of the Company becomes an affiliate or associated person of an Underwriter.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">No Fiduciary Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company acknowledges and agrees that the Underwriters&#8217; responsibility to the Company is solely contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates or any selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement.  Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters for the shares and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial interests.  The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Underlying Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The shares of Common Stock underlying the Preferred Stock shall be issued free of legends.  If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all restrictive legends.  If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Warrant Shares) is not effective or is not otherwise available for the sale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any holder thereof to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Board Composition and Board Designations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall ensure that&#58; (i)&#160;the qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and with the listing requirements of the Trading Market and (ii)&#160;if applicable, at least one member of the Board of Directors qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Securities Laws Disclosure&#59; Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At the request of the Representative, by 9&#58;00 a.m. (New York City time) on the date hereof, the Company shall issue a press release disclosing the material terms of the Offering.  The Company and the Representative shall consult with each other in issuing any other press releases with respect to the Offering, and neither the Company nor any Underwriter shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.  The Company will not issue press releases or engage in any other publicity, without the Representative&#8217;s prior written consent, for a period ending at 5&#58;00 p.m. (New York City time) on the first business day following the 45th day following the Closing Date, other than normal and customary releases issued in the ordinary course of the Company&#8217;s business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Shareholder Rights Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Underwriter of the Securities is an &#8220;Acquiring Person&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Reservation of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares and Conversion Shares pursuant to this Agreement and shall reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Warrant Shares pursuant to any exercise of the Warrants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Listing of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Closing Shares, Option Shares and Underlying Shares on such Trading Market and promptly secure the listing of all of the Closing Shares, Option Shares and Underlying Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock traded on any other Trading Market, it will then include in such application all of the Closing Shares, Option Shares and Underlying Shares, and will take such other action as is necessary to cause all of the Closing Shares, Option Shares and Underlying Shares to be listed or quoted on such other Trading Market as promptly as possible.  The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market.  The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Subsequent Equity Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">From the date hereof until ninety (90) days following the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">From the date hereof until one hundred eighty (180) days following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Variable Rate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and&#47;or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price&#59; provided however, that after ninety (90) days following the Closing Date, the Company&#8217;s issuance of shares of Common Stock pursuant to an at-the-market offering facility with the Representative or that after one-hundred and eighty (180) days following the Closing Date, pursuant to the Company&#8217;s existing equity line of credit with Lincoln Park Capital Fund LLC shall not be deemed a Variable Rate Transaction hereunder.  Any Underwriter shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding the foregoing, this Section 4.20 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Research Independence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company acknowledges that each Underwriter&#8217;s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter&#8217;s research analysts may hold and make statements or investment recommendations and&#47;or publish research reports with respect to the Company and&#47;or </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the offering that differ from the views of its investment bankers.  The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter&#8217;s investment banking divisions.  The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFAULT BY UNDERWRITERS</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If on the Closing Date or any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the Closing Securities or Option Securities, as the case may be, which such Underwriter has agreed to purchase and pay for on such date (otherwise than by reason of any default on the part of the Company), the Representative, or if the Representative is the defaulting Underwriter, the non-defaulting Underwriters, shall use their reasonable efforts to procure within 36 hours thereafter one or more of the other Underwriters, or any others, to purchase from the Company such amounts as may be agreed upon and upon the terms set forth herein, the Closing Securities or Option Securities, as the case may be, which the defaulting Underwriter or Underwriters failed to purchase.  If during such 36 hours the Representative shall not have procured such other Underwriters, or any others, to purchase the Closing Securities or Option Securities, as the case may be, agreed to be purchased by the defaulting Underwriter or Underwriters, then  (a) if the aggregate number of  Closing Securities or Option Securities, as the case may be, with respect to which such default shall occur does not exceed 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the other Underwriters shall be obligated, severally, in proportion to the respective numbers of Closing Securities or Option Securities, as the case may be, which they are obligated to purchase hereunder, to purchase the Closing Securities or Option Securities, as the case may be, which such defaulting Underwriter or Underwriters failed to purchase, or (b) if the aggregate number of Closing Securities or Option Securities, as the case may be, with respect to which such default shall occur exceeds 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the Company or the Representative will have the right to terminate this Agreement without liability on the part of the non-defaulting Underwriters or of the Company except to the extent provided in Article VI hereof.  In the event of a default by any Underwriter or Underwriters, as set forth in this Article V, the applicable Closing Date may be postponed for such period, not exceeding seven days, as the Representative, or if the Representative is the defaulting Underwriter, the non-defaulting Underwriters, may determine in order that the required changes in the Prospectus or in any other documents or arrangements may be effected.  The term &#8220;Underwriter&#8221; includes any Person substituted for a defaulting Underwriter.  Any action taken under this Section shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNIFICATION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification of the Underwriters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Underwriters, and each dealer selected by each Underwriter that participates in the offer and sale of the Securities (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Selected Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and each of their respective directors, officers and employees and each Person, if any, who controls such Underwriter or any Selected Dealer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controlling Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within the </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such Underwriter and any third party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (i) any Preliminary Prospectus, if any, the Registration Statement or the Prospectus (as from time to time each may be amended and supplemented)&#59; (ii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities, including any &#8220;road show&#8221; or investor presentations made to investors by the Company (whether in person or electronically)&#59; or (iii) any application or other document or written communication (in this Article VI, collectively called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, Trading Market or any securities exchange&#59; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon and in conformity with written information furnished to the Company with respect to the applicable Underwriter by or on behalf of such Underwriter expressly for use in any Preliminary Prospectus, if any, the Registration Statement or Prospectus, or any amendment or supplement thereto, or in any application, as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Preliminary Prospectus, if any, the indemnity agreement contained in this Section 6.1 shall not inure to the benefit of  an Underwriter to the extent that any loss, liability, claim, damage or expense of such Underwriter results from the fact that a copy of the Prospectus was not given or sent to the Person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale of the Securities to such Person as required by the Securities Act and the rules and regulations thereunder, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under this Agreement. The Company agrees promptly to notify each Underwriter of the commencement of any litigation or proceedings against the Company or any of its officers, directors or Controlling Persons in connection with the issue and sale of the Public Securities or in connection with the Registration Statement or Prospectus.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity may be sought against the Company pursuant to Section 6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case may be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter or such Selected Dealer, as the case may be) and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter, such Selected Dealer or Controlling Person unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such action, or (iii) such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them which are different from or additional to those available to the Company (in which case the Company shall not have the right to direct the defense of such action on behalf </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the indemnified party or parties), in any of which events the reasonable fees and expenses of not more than one additional firm of attorneys selected by such Underwriter (in addition to local counsel), Selected Dealer and&#47;or Controlling Person shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter, Selected Dealer or Controlling Person shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of any settlement of such action which approval shall not be unreasonably withheld.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, officers and employees and agents who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made in any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, written information furnished to the Company with respect to such Underwriter by or on behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or in any such application. In case any action shall be brought against the Company or any other Person so indemnified based on any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against such Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other Person so indemnified shall have the rights and duties given to such Underwriter by the provisions of this Article VI. Notwithstanding the provisions of this Section 6.3, no Underwriter shall be required to indemnify the Company for any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter.  The Underwriters' obligations in this Section 6.3 to indemnify the Company are several in proportion to their respective underwriting obligations and not joint.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Contribution Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to provide for just and equitable contribution under the Securities Act in any case in which (i) any Person entitled to indemnification under this Article VI makes a claim for indemnification pursuant hereto but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article VI provides for indemnification in such case, or (ii) contribution under the Securities Act, the Exchange Act or otherwise may be required on the part of any such Person in circumstances for which indemnification is provided under this Article VI, then, and in each such case, the Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities, claims, damages and expenses of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such proportions that such Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing on the cover page of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the balance&#59; provided, that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section, each director, officer and </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employee of such Underwriter or the Company, as applicable, and each Person, if any, who controls such Underwriter or the Company, as applicable, within the meaning of Section 15 of the Securities Act shall have the same rights to contribution as such Underwriter or the Company, as applicable.  Notwithstanding the provisions of this Section 6.4, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter.  The Underwriters' obligations in this Section 6.4 to contribute are several in proportion to their respective underwriting obligations and not joint.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Contribution Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">contributing party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this Section 6.4 are intended to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, by notice to the Company&#58; (i)&#160;if any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the immediate future materially disrupt, general securities markets in the United States&#59; or (ii)&#160;if trading on any Trading Market shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction, or (iii)&#160;if the United States shall have become involved in a new war or an increase in major hostilities, or (iv)&#160;if a banking moratorium has been declared by a New York State or federal authority, or (v)&#160;if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets, or (vi)&#160;if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the Representative&#8217;s reasonable opinion, make it inadvisable to proceed with the delivery of the Securities, or (vii)&#160;if the Company is in material breach of any of its representations, warranties or covenants hereunder, or (viii)&#160;if the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions as in the Representative&#8217;s judgment would make it </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impracticable to proceed with the offering, sale and&#47;or delivery of the Securities or to enforce contracts made by the Underwriters for the sale of the Securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event this Agreement shall be terminated pursuant to Section 7.1(a), within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable out of pocket expenses related to the transactions contemplated herein then due and payable, including the fees and disbursements of EGS up to $50,000 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Article VI shall not be in any way effected by such election or termination or failure to carry out the terms of this Agreement or any part hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. Notwithstanding anything herein to the contrary, the Investment Banking Agreements, dated October 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">October 2022 Engagement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and March 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">March 2023 Engagement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and collectively with the October 2022 Engagement Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Engagement Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between the Company and the Representative, shall continue to be effective and the terms therein, including, without limitation, Section 4(d) and Section 5 of the Engagement Agreements with respect to any future offerings, shall continue to survive and be enforceable by the Representative in accordance with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreements and this Agreement, the terms of this Agreement shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of&#58; (a) the time of transmission, if such notice or communication is delivered via e-mail attachment at the email address set forth on the signature pages attached hereto at or prior to 5&#58;30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail attachment at the e-mail address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5&#58;30 p.m. (New York City time) on any Trading Day, (c) the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.  The address for such notices and communications shall be as set forth on the signature pages attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendments&#59; Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Representative.   No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.  Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.   If either party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Article VI, the prevailing party in such Action or Proceeding shall be reimbursed by the other party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The representations and warranties contained herein shall survive the Closing and the Option Closing, if any, and the delivery of the Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.  In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that </font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Underwriters and the Company will be entitled to specific performance under the Transaction Documents.  The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Saturdays, Sundays, Holidays, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The parties agree that each of them and&#47;or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY RIGHT TO TRIAL BY JURY. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(Signature Pages Follow)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement among the Company and the several Underwriters in accordance with its terms.</font></div><div style="margin-top:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-top:12pt;padding-left:180pt;padding-right:-42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</font></div><div style="margin-top:24pt;padding-left:180pt;padding-right:-48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Brian M. Strem, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:204pt;padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Brian M. Strem, Ph.D.&#160;&#160;&#160;&#160;<br>Title&#58;   President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">332 Encinitas Boulevard, Suite 102</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encinitas, CA 92024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Chief Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Copy to&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Burns &#38; Levinson LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">125 High Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02110</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Robert Petitt, Esq.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted on the date first above written.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LADENBURG THALMANN &#38; CO. INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As the Representative of the several </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Underwriters listed on Schedule I</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Ladenburg Thalmann &#38; Co. Inc.</font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Nicholas Stergis&#160;&#160;&#160;&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Nicholas Stergis</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Managing Director</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Address for Notice&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">640 Fifth Avenue, 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, NY 10019</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; General Counsel</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Copy to&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ellenoff Grossman &#38; Schole LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1345 Avenue of the Americas</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, NY 10105</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Michael Nertney, Esq.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:83.52pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SCHEDULE I</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule of Underwriters</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Underwriters</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Closing Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Closing Preferred Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Closing Class C Warrants</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Closing Class D Warrants</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Closing Purchase Price</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ladenburg Thalmann &#38; Co. Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,447,628</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,908</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,060,000.00</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1,447,628</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3,908</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5,000,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5,000,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$5,060,000.00</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>exhibit31-seriesfpreferred.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieb4b8f561ee848bbafbfd21746c60fff_1"></div><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit 3.1</font></div></div><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATE OF DESIGNATION OF PREFERENCES, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RIGHTS AND LIMITATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERIES F CONVERTIBLE PREFERRED STOCK</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PURSUANT TO SECTION 151 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DELAWARE GENERAL CORPORATION LAW</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        The undersigned, Brian M. Strem, Ph.D., does hereby certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                1. He is the President, Chief Executive Officer and Secretary of Kiora Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, 16,725.9 of which have been issued.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                3. The following resolutions were duly adopted by the board of directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.01 par value per share, issuable from time to time in one or more series&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Underwriting Agreement, up to 3,908 shares of the preferred stock which the Corporation has the authority to issue, as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS OF PREFERRED STOCK</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the purposes hereof, the following terms shall have the following meanings&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alternate Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(d). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(c)(iv).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Corporation&#8217;s common stock, par value $0.01 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the sum of the Stated Value at issue.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(a).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(b). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance with the terms hereof.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means United States generally accepted accounting principles.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given such term in Section 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 5.</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8(d).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(a).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Issue Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Ladenburg Thalmann &#38; Co. Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(c).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stated Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a day on which the principal Trading Market is open for business.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question&#58; the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means VStock Transfer, LLC, the current transfer agent of the Corporation with a mailing address of 18 Lafayette Place, Woodmere, New York 11598 and an email address of 0-k&#64;vstocktransfer.com, and any successor transfer agent of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Underwriting Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the underwriting agreement, dated as of June 2, 2023, among the Corporation and the Representative, as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.  </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Designation, Amount and Par Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The series of preferred stock shall be designated as its Series F Convertible Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the number of shares so designated shall be up to 3,908 (which shall not be subject to increase without the written consent of the holders of a majority of the then outstanding shares of the Preferred Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)). Each share of Preferred </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock shall have a par value of $0.01 per share and a stated value equal to $999.90, subject to increase set forth in Section 3 below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stated Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Preferred Stock will initially be issued in book-entry form and shall initially be represented only by one or more global certificates deposited with the Depository Trust Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and registered in the name of Cede &#38; Co., a nominee of DTC, or as otherwise directed by DTC.  As between the Corporation and a beneficial owner of Preferred Stock shall have all of the rights and remedies of a Holder hereunder.  In addition, a beneficial owner of Preferred Stock has the right, upon written notice by such beneficial owner to the Corporation, to request the exchange of some or all of such beneficial owner&#8217;s interest in Preferred Stock represented by one or more global Preferred Stock certificates deposited with Cede &#38; Co. (or its successor) for a physical Preferred Stock certificate (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock Certificate Request Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the date of delivery of such Preferred Stock Certificate Request Notice by a beneficial owner, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock Certificate Request Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the deemed surrender upon delivery by the beneficial owner of a number of global shares of Preferred Stock for the same number of shares of Preferred Stock represented by a physical stock certificate, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and such physical certificate(s), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Stock Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Upon delivery of a Preferred Stock Certificate Request Notice, the Corporation shall promptly effect the Preferred Stock Exchange and shall promptly issue and deliver to the beneficial owner a physical Preferred Stock Certificate for such number of shares of Preferred Stock represented by its interest in such global certificates in the name of the beneficial owner.  Such Preferred Stock Certificate shall be dated the original issue date and shall be executed by an authorized signatory of the Corporation.  In connection with a Preferred Stock Exchange, the Corporation agrees to deliver the Preferred Stock Certificate to the Holder within two (2) Business Days of the delivery of a properly completed and executed Preferred Stock Certificate Request Notice pursuant to the delivery instructions in the Preferred Stock Certificate Request Notice.  The Corporation covenants and agrees that, upon the date of delivery of the properly completed and executed Preferred Stock Certificate Request Notice, the Holder shall be deemed to be the holder of the Preferred Stock Certificate and further, for purposes of Regulation SHO, a Holder whose interest in this Preferred Stock is a beneficial interest in certificate(s) representing this Preferred Stock held in book-entry form through DTC shall be deemed to have converted its interest in this Preferred Stock upon instructing its broker that is a DTC participant to convert its interest in this Preferred Stock,  and, notwithstanding anything to the contrary set forth herein, the Preferred Stock Certificate shall be deemed for all purposes to represent all of the terms and conditions of the Preferred Stock evidenced by such global Preferred Stock certificates and the terms hereof.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.  No other dividends shall be paid on shares of Preferred Stock.  The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously complies with this provision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock. The Corporation shall mail written notice of any such Liquidation, not less than forty-five (45) days prior to the payment date stated therein, to each Holder.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Conversions at Option of Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by e-mail such Notice of Conversion to the Corporation (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.  To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Preferred Stock to the Corporation unless all of the shares of Preferred Stock represented thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Preferred Stock promptly following the Conversion Date at issue.  Shares of Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be reissued. Notwithstanding the foregoing in this Section 6(a), a holder whose interest in the Preferred Stock is a beneficial interest in certificate(s) representing the Preferred Stock held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect conversions made pursuant to this Section 6(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for conversion, complying with the procedures to effect conversions that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder&#8217;s right to elect to receive Preferred Stock in certificated form pursuant to Section 2, in which case this sentence shall not apply.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The conversion price for the Preferred Stock shall equal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to adjustment herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.69pt;text-decoration:underline">Mechanics of Conversion</font></div><div style="text-align:justify"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt;text-decoration:underline">Delivery of Conversion Shares Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Corporation shall deliver, or cause to be delivered, to the converting Holder (A) the number of Conversion Shares being acquired upon the conversion of the Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions, and (B) a bank check in the amount of accrued and unpaid dividends, if any.  The Corporation shall use its best efforts to deliver the Conversion Shares required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust Company or another established clearing corporation performing similar functions. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standard Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Corporation&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Conversion. Notwithstanding the foregoing, with respect to any Notice(s) of Conversion delivered by 12&#58;00 p.m. (New York City time) on the Original Issue Date, the Corporation agrees to deliver the Conversion Shares subject to such notice(s) by 4&#58;00 p.m. (New York City time) on the Original Issue Date, and the Original Issue Date being deemed the &#8220;Share Delivery Date&#8221; with respect to any Notice(s) of Conversion.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt;text-decoration:underline">Failure to Deliver Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.01pt;text-decoration:underline">Obligation Absolute&#59; Partial Liquidated Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder.  In the event a Holder shall elect to convert any or all of the Stated Value of its Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and&#47;or enjoining conversion of all or part of the Preferred Stock of such Holder shall have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated Value of Preferred </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock which is subject to the injunction, which bond shall remain in effect until the completion of arbitration&#47;litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment.  In the absence of such injunction, the Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such conversion, the Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of Preferred Stock being converted, $50 per Business Day (increasing to $100 per Business Day on the third Business Day and increasing to $200 per Business Day on the tenth Business Day after such Share Delivery Date) for each Business Day after the Share Delivery Date until such Conversion Shares are delivered or Holder rescinds such conversion.  Nothing herein shall limit a Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief.  The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to any other rights available to the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specific performance and&#47;or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver the Conversion Shares upon conversion of the shares of Preferred Stock as required pursuant to the terms hereof. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Reservation of Shares Issuable Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock.  The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock.   As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from converting fractional shares of Preferred Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.34pt;text-decoration:underline">Transfer Taxes and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.  The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Conversion Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder&#8217;s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder&#8217;s Affiliates (such Persons, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attribution Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock with respect to which </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation  subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.  To the extent that the limitation contained in this Section 6(d) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and of how many shares of Preferred Stock are convertible shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&#8217;s determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination.  In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following&#58; (i) the Corporation&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request (which may be via email) of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any shares of Preferred Stock, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Stock held by the applicable Holder.  A Holder, upon notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 6(d) applicable to its Preferred Stock provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Preferred Stock held by the Holder and the provisions of this Section 6(d) shall continue to apply.  Any such increase in the Beneficial Ownership Limitation will not be effective until the 61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day after such notice is delivered to the Corporation and shall only apply to such Holder and no other Holder.  The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(d) to correct this paragraph (or any portion </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Stock Dividends and Stock Splits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Corporation, at any time while this Preferred Stock is outstanding&#58; (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event.  Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Subsequent Rights Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Holder of will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder&#8217;s Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Pro Rata Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transaction) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alternate Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock).  For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.  If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conversion of this Preferred Stock following such Fundamental Transaction.  To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration.  The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to assume in writing all of the obligations of the Corporation under this Certificate of Designation in accordance with the provisions of this Section 7(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation referring to the &#8220;Corporation&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation with the same effect as if such Successor Entity had been named as the Corporation herein.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All calculations under this Section 7 shall be made to the nearest cent or the nearest 1&#47;100th of a share, as the case may be.  For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.02pt;text-decoration:underline">Notice to the Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt;text-decoration:underline">Adjustment to Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall promptly deliver to each Holder by email a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.  </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.34pt;text-decoration:underline">Notice to Allow Conversion by Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered  by email to each Holder at its last email address as it shall appear upon the stock books of the Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.  To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.  The Holder shall remain entitled to convert the Conversion Amount of this Preferred Stock (or any part hereof) during the 20-day period commencing on the date of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at the address set forth above, Attention&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer, e-mail address bstrem&#64;kiorapharma.com, or such other e-mail address or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8.  Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Corporation.  Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via  e-mail at the e-mail address set forth in this Section 8 prior to 5&#58;30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5&#58;30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Absolute Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages, and accrued dividends, as applicable, on the shares of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.  </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Lost or Mutilated Preferred Stock Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Holder&#8217;s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof.  All legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by this Certificate of Designation (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding.  The Corporation and each Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. The Corporation and each Holder hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby.  If the Corporation or any Holder shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&#8217; fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders.  The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion.  Any waiver by the Corporation or a Holder must be in writing.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.02pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances.  If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Next Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.68pt;text-decoration:underline">Status of Converted or Redeemed Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any shares of Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series F Convertible Preferred Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*********************</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><div id="ieb4b8f561ee848bbafbfd21746c60fff_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RESOLVED, FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of Delaware law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        IN WITNESS WHEREOF, the undersigned has executed this Certificate this 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of June, 2023.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Brian M. Strem, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Name&#58;  Brian M. Strem, Ph.D.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Title&#58;    President, Chief Executive Officer and Secretary</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE OF CONVERSION</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED STOCK)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The undersigned hereby elects to convert the number of shares of Series F Convertible Preferred Stock indicated below into shares of common stock, par value $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), of Kiora Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conversion calculations&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:32.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.346%"><tr><td style="width:1.0%"></td><td style="width:54.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date to Effect Conversion&#58; _____________________________________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of Preferred Stock owned prior to Conversion&#58; _______________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of Preferred Stock to be Converted&#58; ________________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stated Value of shares of Preferred Stock to be Converted&#58; ____________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of Common Stock to be Issued&#58; ___________________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Conversion Price&#58;____________________________________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of Preferred Stock subsequent to Conversion&#58; ________________</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address for Delivery&#58; ______________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">or</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DWAC Instructions&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Broker no&#58; _________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Account no&#58; ___________</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;HOLDER&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;___________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Name&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Title&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">       </font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>exhibit43-warrantagencyagr.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i432860a3a2c8486d8b8af94ed272555d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit 4.3</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">KIORA PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VSTOCK TRANSFER, LLC, as</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Warrant Agent</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Warrant Agency Agreement</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of June 6, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WARRANT AGENCY AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WARRANT AGENCY AGREEMENT, dated as of June 6, 2023 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and VStock Transfer, LLC, a New York limited liability trust company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VStock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W I T N E S S E T H</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, pursuant to an offering by the Company of Warrants (as defined below), the Company wishes to issue Warrants in book entry form entitling the respective holders of the Warrants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, which term shall include a Holder&#8217;s transferees, successors and assigns and &#8220;Holder&#8221; shall include, if the Warrants are held in &#8220;street name&#8221;, a Participant (as defined below) or a designee appointed by such Participant) to purchase an aggregate of up to 10,000,000 shares of Common Stock underlying the Warrants (as defined below) upon the terms and subject to the conditions hereinafter set forth (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="text-align:justify;text-indent:14.4pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Company wishes the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to act on behalf of the Company, in connection with the issuance, registration, transfer, exchange, exercise and replacement of the Warrants.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes of this Agreement, the following terms have the meanings indicated&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed to it in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which the Nasdaq Stock Market is authorized or required by law or other governmental action to close.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#8220;Class C Warrants&#8221; means Common Stock Purchase Warrant of the Company with a term of exercise of five (5) years following the Initial Exercise Date.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) (c) &#8220;Class D Warrants&#8221; means Common Stock Purchase Warrant of the Company with a term of exercise of one (1) year following the Initial Exercise Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Close of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; on any given date means 5&#58;00 p.m., New York City time, on such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that if such date is not a Business Day, it means 5&#58;00 p.m., New York City time, on the next succeeding Business Day.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an individual, corporation, association, partnership, limited liability company, joint venture, trust, unincorporated organization, government or political subdivision thereof or governmental agency or other entity.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)   &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively the Class C Warrants and Class D Warrants.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a certificate in substantially the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1-A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (as it relates to the Class C Warrants) or Exhibit 1-B hereto (as it relates to the Class D Warrants), representing such number of Warrant Shares (as defined below) as is indicated therein, provided that any reference to the delivery of a Warrant Certificate in this Agreement shall include delivery of notice from the Depository or a Participant (each as defined below) of the transfer or exercise of the Warrant in the form of a Global Warrant (as defined below).</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the shares of Common Stock underlying the Warrants and issuable upon exercise of the Warrants.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificates. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Appointment of Successor Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the express terms or conditions hereof (and no implied terms and conditions), and the Warrant Agent hereby accepts such appointment. The Company may from time to time appoint such Co-Warrant Agents as it may, in its sole discretion, deem necessary or desirable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">upon ten (10) calendar days&#8217; prior written notice to the Warrant Agent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Warrant Agent shall have no duty to supervise, and shall in no event be liable for, the acts or omissions of any such Co-Warrant Agent.  In the event the Company appoints one or more co-Warrant Agents, the respective duties of the Warrant Agent and any Co-Warrant Agent shall be as the Company shall reasonably determine, provided that such duties and determination are consistent with the terms and provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Global Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Warrants shall be issuable in book entry form.  All of the Warrants shall initially be represented by one or more Global Warrants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Global Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and, each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Global Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), deposited with the Warrant Agent and registered in the name of Cede &#38; Co., a nominee of The Depository Trust Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Depository</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), or as otherwise directed by the Depository. Ownership of beneficial interests in the Warrants, shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depository or its nominee for each Global Warrant or (ii) institutions that have accounts with the Depository (such institution, with respect to a Warrant in its account, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  For purposes of Regulation SHO, a holder whose interest in a Global Warrant is a beneficial interest in certificate(s) representing such Warrant held in book-entry form through the Depository shall be deemed to have exercised its interest in such Warrant upon instructing its broker that is a Participant to exercise its interest in such Warrant, provided that in each such case payment of the applicable aggregate Exercise Price (other than in the case of a cashless exercise) is delivered by such Participant within the earlier of (i) two trading days and (ii) the number of trading days comprising the Standard Settlement Period, in each case following such instruction.  As used herein, &#8220;Standard Settlement Period&#8221; means the standard settlement period, expressed in a number of trading days, on the Company&#8217;s primary trading market with respect to the Common Stock as in effect on the date of delivery of the Exercise Notice.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If the Depository subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation each Global Warrant, and the Company shall deliver to each Holder a Warrant Certificate.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)  A Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate Request Notice (as defined below).  Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such Holder&#8217;s Global Warrants for a Warrant Certificate, evidencing the same number of Warrants, which request shall be in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Certificate Request Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and the date of delivery of such Warrant Certificate Request Notice by the Holder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Certificate Request Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and the deemed surrender upon delivery by the Holder of a number of Global Warrants for the same number of Warrants evidenced by a Warrant Certificate, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Warrant Agent shall promptly effect the Warrant Exchange and shall promptly instruct the Company to issue and deliver, at the expense of the Company, to the Holder a Warrant Certificate, for such number of Warrants in the name set forth in the Warrant Certificate Request Notice.  Such Warrant Certificate shall be dated the original issue date of the Warrants, shall be executed by manual signature by an authorized signatory of the Company, and shall be in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1-A or Exhibit 1-B, as the case may be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In connection with a Warrant Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Warrant Certificate, to the Holder within three (3) Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warrant Certificate Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding anything herein to the contrary, the Company shall act as warrant agent with respect to any physical Warrant Certificate issued pursuant to this section and VStock shall have no further obligations under this Agreement with respect to any physical Warrant Certificates issued under this Agreement.  If the Company fails for any reason to deliver to the Holder the Warrant Certificate subject to the Warrant Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Warrant Certificate (based on the VWAP (as defined in the Warrants) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day after such Warrant Certificate Delivery Date until such Warrant Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange.  In no event shall the Warrant Agent be liable for the Company&#8217;s failure to deliver the Warrant Certificate by the Warrant Certificate Delivery Date. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be the holder of the Warrant Certificate, as applicable, and, notwithstanding anything to the contrary set forth herein, the Warrant Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants, evidenced by such Warrant Certificate, and the terms of this Agreement, other than Sections 3(c) and 9 herein, shall not apply to the Warrants evidenced by the Warrant Certificate.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Warrant Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Warrant Certificate, together with the form of election to purchase Common Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and the form of assignment to be printed on the reverse thereof, shall be in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1-A or Exhibit 1-B, as the case may be,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Countersignature and Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Warrant Certificates shall be executed on behalf of the Company by its Chief Executive Officer, Chief Financial Officer or Vice President, either manually or by .pdf via email signature. In case any officer of the Company who shall have signed any of the Warrant Certificates shall cease to be such officer of the Company, such Warrant Certificates, nevertheless, may be issued and delivered with the same force and effect as though the Person who signed such Warrant Certificate had not ceased to be such officer of the Company&#59; and any Warrant Certificate may be signed on behalf of the Company by any Person who, at the actual date of the execution of such Warrant Certificate, shall be a proper officer of the Company to sign such Warrant Certificate, although at the date of the execution of this Agreement any such Person was not such an officer.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company will keep or cause to be kept, at its office designated for such purposes, books for registration and transfer of the Warrant Certificates issued hereunder. Such books shall show the names and addresses of the respective Holders of the Warrant Certificates, the number of warrants evidenced on the face of each such Warrant Certificate and the date of each such Warrant Certificate.  The Company will create a special account for the issuance of Warrant Certificates.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer, Split Up, Combination and Exchange of Warrant Certificates&#59; Mutilated, Destroyed, Lost or Stolen Warrant Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. With respect to the  Global Warrant, subject to the provisions of the Warrant Certificate, and the last sentence of this first paragraph of Section 6 and subject to applicable law, rules or regulations, or any &#8220;stop transfer&#8221; instructions the Company may give to the Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close of Business on the Termination Date (as such term is defined in the Warrant Certificate), any Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants may be transferred, split up, combined or exchanged for another Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common Stock as the Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring to transfer, split up, combine or exchange any Warrant Certificate or Global Warrant shall make such request in writing delivered to the Warrant Agent or the Company, as applicable, and shall surrender the Warrant Certificate or Warrant Certificates, together with the required form of assignment and certificate duly executed and properly completed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and such other documentation as the Warrant Agent or the Company, as applicable, may reasonably request, to be transferred, split up, combined or exchanged at the office of the Warrant Agent designated for such purpose, provided that no such surrender is applicable to the Holder of a Global Warrant. Any requested transfer of Warrants, whether in book-entry form or certificate form, shall be accompanied by evidence of authority of the party making such request</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that may be reasonably required by the Warrant Agent or the Company, as applicable. Thereupon the Company shall, subject to the last sentence of this first paragraph of Section 6, countersign and deliver to the Person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer, split up, combination or exchange of Warrant Certificates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Warrant Agent shall not have any duty or obligation to take any action under any section of this Agreement that requires the payment of taxes and&#47;or charges unless and until it is satisfied that all such payments have been made.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case of loss, theft or destruction, of indemnity or security reasonably acceptable to the Company, and satisfaction of any other reasonable requirements established by Section 8-405 of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender to the Company and cancellation of the Warrant Certificate if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise of Warrants&#59; Exercise Price&#59; Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable on the Termination Date (as such term is defined in the Warrant Certificate).  Subject to the foregoing and to Section 7(b) below, the Holder of a Warrant may exercise the Warrant, in whole or in part upon surrender of the  Warrant Certificate, if required, with the properly completed and duly executed Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and payment of the Exercise Price (unless exercised via a cashless exercise), which may be made, at the option of the Holder, by wire transfer or by certified or official bank check in United States dollars, to the Warrant Agent at the office of the Warrant Agent designated for such purposes. In the case of the Holder of a Global Warrant, the Holder shall deliver the duly executed Exercise Notice and the payment of the Exercise Price as described herein. Notwithstanding any other provision in this Agreement, a holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the Depository (or another established clearing corporation performing similar functions) shall effect exercises by delivering to the Depository (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that is required by the Depository (or such other clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained by the Warrant Agent in connection with the services provided under this Agreement will be in its name and that the Warrant Agent may receive investment earnings in connection with the investment at Warrant Agent risk and for its benefit of funds held in those accounts from time to time.  Neither the Company nor the Holders will receive interest on any deposits or Exercise Price. No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice be required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Upon receipt of an Exercise Notice for a Cashless Exercise, the Warrant Agent shall deliver a copy of the Exercise Notice to the Company and request from the Company, and the Company shall promptly calculate and transmit to the Warrant Agent in writing, the number of Warrant Shares issuable in connection with such Cashless Exercise. The Warrant Agent shall have no obligation under this Agreement to calculate, the number of Warrant Shares issuable in connection with a Cashless Exercise, nor shall the Warrant Agent have any duty or obligation to investigate or confirm whether the Company&#8217;s determination of the number of Warrant Shares issuable upon such exercise, pursuant to this Section 7, is accurate or correct.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Upon exercise of the Warrant Certificate pursuant to Section 2 of the Warrant Certificate, the Warrant Agent or the Company, as applicable, shall cause the Warrant Shares underlying such Warrant Certificate, or Global Warrant, to be delivered to or upon the order of the Holder of such Warrant Certificate, or  Global Warrant, registered in such name or names as may be designated by such Holder, no later than the Warrant Share Delivery Date (as such term is defined in the Warrant Certificate). If the Company is then a participant in the DWAC system of the Depository and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised via Cashless Exercise, then the certificates for Warrant Shares shall be transmitted by the Warrant Agent to the Holder by crediting the account of the Holder&#8217;s broker with the Depository through its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Sections 2(d)(i) or 2(d)(iv) of the Warrant Certificate, such obligation shall be solely that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of the Company and not that of the Warrant Agent. Notwithstanding anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any Holder fails to duly deliver payment to the Warrant Agent or the Company, as applicable, of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of such Holder&#8217;s Warrant as set forth in Section 7(a) hereof by the Warrant Share Delivery Date, the Warrant Agent or the Company, as applicable, will not be obligated to deliver such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant Share Delivery Date shall be deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant Agent or the Company, as applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"> </font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company maintained with the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise the Company via email at the end of each day on which exercise notices are received, or funds for the exercise of any Warrant are received, of the amount so deposited to its account. </font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) In case the Holder of any Warrant Certificate shall exercise fewer than all Warrants evidenced thereby, upon the request of the Holder, a new Warrant Certificate evidencing the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued by the Company to the Holder of such Warrant Certificate or to his duly authorized assigns in accordance with Section 2(d)(ii) of the Warrant Certificate, subject to the provisions of Section 6 hereof.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cancellation and Destruction of Warrant Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled form, shall be canceled by it, and no Warrant Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Agreement. The Company shall cancel and retire any other Warrant Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at the written request of the Company, destroy such canceled Warrant Certificates, and in such case shall deliver a certificate of destruction thereof to the Company, subject to any applicable law, rule or regulation requiring the Warrant Agent to retain such canceled certificates.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Representations&#59; Reservation and Availability of Shares of Common Stock or Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) This Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery hereof by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due execution thereof by the Warrant Agent pursuant hereto and payment therefor by the Holders, constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms and entitled to the benefits hereof&#59; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors&#8217; rights generally or by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) As of the date hereof, the authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which 2,024,270 shares of Common Stock are issued and outstanding, and 11,613,483 shares of Common Stock are reserved for issuance upon exercise of warrants (including the Warrants), (ii) 10,000,000 shares of preferred stock, 7 of which are issued and outstanding and 52 shares of Common Stock are reserved for issuance upon conversion of the Preferred Stock&#59; and (iii) 298,848 shares of Common Stock are authorized for issuance to employees, consultants and directors pursuant to the Company&#8217;s stock plan, under which options to purchase 202,126 shares are issued and outstanding. There are no other outstanding obligations, warrants, options or other rights to subscribe for or purchase from the Company any class of capital stock of the Company.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common Stock or its authorized and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Warrant Agent will create a special account for the issuance of Common Stock upon the exercise of Warrants.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) The Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon exercise of the Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may be payable in respect of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall have been paid (any such tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender) or until it has been established to the Company&#8217;s and the Warrant Agent&#8217;s reasonable satisfaction that no such tax or governmental charge is due.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Person in whose name any certificate for shares of Common Stock is issued (or to whose broker&#8217;s account is credited shares of Common Stock through the DWAC system) upon the exercise of Warrants shall for all purposes be deemed to have become the holder of record for the Common Stock represented thereby on, and such certificate shall be dated, the date on which submission of the Exercise Notice was made, provided that the Warrant Certificate evidencing such Warrant was duly surrendered (but only if required herein) and payment of the Exercise Price (and any applicable transfer taxes) was received on or prior to the Warrant Share Delivery Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, if the date of submission of the Exercise Notice is a date upon which the Common Stock transfer books of the Company are closed, such Person shall be deemed to have become the record holder of such shares on, and such certificate shall be dated, the next succeeding day on which the Common Stock transfer books of the Company are open.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Exercise Price, the number of shares covered by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section 3 of the Warrant Certificate.  In the event that at any time, as a result of an adjustment made pursuant to Section 3 of the Warrant Certificate, the Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained in Section 3 of the Warrant Certificate, and the provisions of Sections 7, 9 and 13 of this Agreement with respect to the shares of Common Stock shall apply on like terms to any such other shares.  All Warrants originally issued by the Company subsequent to any adjustment made to the Exercise Price pursuant to the Warrant Certificate shall evidence the right to purchase, at the adjusted Exercise Price, the number of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment as provided herein.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of Adjusted Exercise Price or Number of Shares of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Whenever the Exercise Price or the number of shares of Common Stock issuable upon the exercise of each Warrant Certificate is adjusted as provided in Section 11 or 13, the Company shall (a) promptly prepare a certificate setting forth the Exercise Price of each Warrant Certificate, as so adjusted, and a brief, reasonably detailed statement of the facts accounting for such adjustment, (b) promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate and (c) instruct the Warrant Agent, at the Company&#8217;s expense, to send a brief summary thereof to each Holder of a Warrant Certificate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Warrant Agent shall be fully protected in relying on such certificate and on any adjustment or statement therein contained and shall have no duty or liability with respect to and shall not be deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such certificate.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fractional Shares of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Company shall not issue fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any fractional Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such fraction to the nearest whole Warrant (rounded up).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed, the actual issuance or distribution in respect thereof shall be made in accordance with Section 2(d)(v) of the Warrant Certificate.</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Concerning the Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Company agrees to pay to the Warrant Agent, pursuant to the fee schedule mutually agreed upon by the parties hereto and provided separately on the date hereof, for all services rendered by it hereunder and, from time to time, its reasonable expenses and counsel fees and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Company covenants and agrees to indemnify and to hold the Warrant Agent harmless against any costs, expenses (including reasonable fees and expenses of its legal counsel), losses or damages, which may be paid, incurred or suffered by or to which it may become subject, arising from or out of, directly or indirectly, any claims or liability resulting from its actions or omissions as Warrant Agent pursuant hereto&#59; provided, that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect to, such costs, expenses, losses and damages incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence, bad faith, or willful misconduct (each as determined by a final non-appealable court of competent jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Warrant Agent under this Agreement will be limited to the amount of annual fees paid by the Company to the Warrant Agent during the twelve (12) months immediately preceding the event for which recovery from the Warrant Agent is being sought.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The costs and expenses incurred by the Warrant Agent in enforcing this right of indemnification shall be paid by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)  Upon the assertion of a claim for which the Company may be required to indemnify the Warrant Agent, the Warrant Agent shall promptly notify the Company of such assertion, and shall keep the other party reasonably advised with respect to material developments concerning such claim. However, failure to give such notice shall not affect the Warrant Agent&#8217;s right to and the Company&#8217;s obligations for indemnification hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Neither party to this Agreement shall be liable to the other party for any consequential, indirect, punitive, special or incidental damages under any provisions of this Agreement or for any consequential, indirect, punitive, special or incidental damages arising out of any act or failure to act hereunder even if that party has been advised of or has foreseen the possibility of such damages. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Notwithstanding anything contained herein to the contrary, the rights and obligations of the parties set forth in this Section&#160;14 shall survive termination of this Agreement, the expiration of the Warrants and&#47;or the resignation, removal or replacement of the Warrant Agent. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase or Consolidation or Change of Name of Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any Person into which the Warrant Agent or any successor Warrant Agent may be merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Warrant Agent or any successor Warrant Agent shall be party, or any Person succeeding to the stock transfer or other shareholder services business of the Warrant Agent or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Warrant Agent under the provisions of Section 17. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Duties of Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following express terms and conditions (and no implied terms and conditions), by all of which the Company, by its acceptance hereof, shall be bound and shall not assume any obligations or relationship of agency or trust with any of the Holders of the Warrants or any other Person&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Warrant Agent may consult with legal counsel selected by it (who may be legal counsel for the Company), and the opinion and advice of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in accordance with such opinion or advice.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer, Chief Financial Officer or Vice President of the Company&#59; and such certificate shall be full authorization and protection to the Warrant Agent, and the Warrant Agent shall incur no liability for or in respect of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate.  The Warrant Agent shall have no duty to act without such a certificate as set forth in this Section 16(b).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Subject to the limitation set forth in Section 14, the Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct (each as determined in a final, non-appealable judgment of a court of competent jurisdiction).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Warrant Certificates (including in the case of any notation in book-entry form to reflect ownership), except its countersignature thereof, by the Company or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) The Warrant Agent shall not have any liability or be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except its countersignature thereof)&#59; nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant Certificate&#59; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change in the number of shares of Common Stock required under the provisions of Section 11 or 13 or responsible for the manner, method or amount of any such change or adjustment or the ascertaining of the existence of facts that would require any such adjustment or change (except with respect to the exercise of Warrants evidenced by Warrant Certificates after actual notice of any adjustment of the Exercise Price)&#59; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued, be duly authorized, validly issued, fully paid and nonassessable.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Each party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out or performing by any party of the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) The Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive Officer, Chief Financial Officer or Vice President of the Company, and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without gross negligence, bad faith or willful misconduct.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) The Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other Person. In the event that the Warrant Agent seeks to exercise a Warrant, and provides the Company with (i) an opinion of counsel to the effect that a public sale or transfer of the Common Stock issuable upon exercise of the Warrant may be made without registration under the 1933 Act and such sale or transfer is effected or (ii) the Purchaser provides reasonable assurances that the Securities can be sold pursuant to an effective registration statement under the Securities Act of 1933, as amended, Rule 144, Section 4(a)(1), or other applicable exemption, the Company shall permit the transfer, and, in the case of the Common Stock issuable upon exercise of the Warrant, promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified by the Holder. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 16(h) may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence or bad faith in the selection and continued employment thereof (which gross negligence and bad faith must be determined by a final, non-appealable judgment of a court of competent jurisdiction).</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) The Warrant Agent shall not be obligated to expend or risk its own funds or to take any action that it believes would expose or subject it to expense or liability or to a risk of incurring expense or liability, unless it has been furnished with assurances of repayment or indemnity satisfactory to it.</font></div><div style="text-align:justify;text-indent:26.55pt"><font><br></font></div><div style="text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) The Warrant Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:26.55pt"><font><br></font></div><div style="text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l) The Warrant Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing&#59; or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </font></div><div><font><br></font></div><div style="text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m) In the event the Warrant Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Warrant Agent hereunder, the Warrant Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Company, the holder of any Warrant or any other Person for refraining from taking such action, unless the Warrant Agent receives written instructions signed by the Company which eliminates such ambiguity or uncertainty to the satisfaction of Warrant Agent. </font></div><div style="text-indent:26.55pt"><font><br></font></div><div style="text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n) This Section 16 shall survive the expiration of the Warrants, the termination of this Agreement and the resignation, replacement or removal of the Warrant Agent.  The costs and expenses incurred in enforcing this right of indemnification shall be paid by the Company.</font></div><div style="text-indent:26.55pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Warrant Agent may resign and be discharged from its duties under this Agreement upon thirty (30) days&#8217; notice in writing sent to the Company and, in the event that the Warrant Agent or one of its affiliates is not also the transfer agent for the Company, to each transfer agent of the Common Stock. In the event the transfer agency relationship in effect between the Company and the Warrant Agent terminates, the Warrant Agent will be deemed to have resigned automatically and be discharged from its duties under this Agreement as of the effective date of such termination, and the Company shall be responsible for sending any required notice thereunder. The Company may remove the Warrant Agent or any successor Warrant Agent upon thirty (30) days&#8217; notice in writing, sent to the Warrant Agent or successor Warrant Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. If the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder of a Warrant Certificate (who shall, with such notice, submit this Warrant Certificate for inspection by the Company), then the Holder of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent, provided that, for purposes of this Agreement, the Company shall be deemed to be the Warrant Agent until a new warrant agent is appointed. Any successor Warrant Agent, whether appointed by the Company or by such a court, shall be a Person, other than a natural person, organized and doing business under the laws of the United States or of a state thereof, in good standing, which is authorized under such laws to exercise stock transfer powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Warrant Agent without further act or deed&#59; but the predecessor Warrant Agent shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">but such predecessor Warrant Agent shall not be required to make any additional expenditure (without prompt reimbursement by the Company) or assume any additional liability in connection with the foregoing. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock and mail a notice thereof in writing to the Holders of the Warrant Certificates. However, failure to give any notice provided for in this Section 17, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the case may be. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 18. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of New Warrant Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property purchasable under the several Warrant Certificates made in accordance with the provisions of this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 19. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notices or demands authorized by this Agreement to be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate to or on the Company, (ii) by the Company or by the Holder of any Warrant Certificate to or on the Warrant Agent or (iii) by the Company or the Warrant Agent to the Holder of any Warrant Certificate, shall be deemed given when in writing (a) on the date delivered, if delivered personally, (b) on the first Business Day following the deposit thereof with Federal Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, (c) on the fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt requested), and (d) the time of transmission, if such notice or communication is delivered via e-mail attachment at or prior to 5&#58;30 p.m. (New York City time) on a Business Day and (e) the next Business Day after the date of transmission, if such notice or communication is delivered via e-mail attachment on a day that is not a Business Day or later than 5&#58;30 p.m. (New York City time) on any Business Day, in each case to the parties at the following addresses (or at such other address for a party as shall be specified by like notice)&#58;</font></div><div><font><br></font></div><div style="padding-left:56.25pt;text-align:justify;text-indent:-15.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;If to the Company, to&#58; </font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kiora Pharmaceuticals, Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 Encinitas Boulevard, Suite 102</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encinitas, CA 92024</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-mail&#58; bstrem&#64;kiorapharma.com</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Brian Strem</font></div><div style="padding-left:56.25pt"><font><br></font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a copy (which shall not constitute notice) to&#58;</font></div><div style="padding-left:56.25pt"><font><br></font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burns &#38; Levinson LLP</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 High Street</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston, MA 02110</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-mail&#58; rpetitt&#64;burnslev.com</font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Robert Petitt</font></div><div style="padding-left:56.25pt"><font><br></font></div><div style="padding-left:56.25pt"><font><br></font></div><div style="padding-left:56.25pt;text-align:justify;text-indent:-15.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If to the Warrant Agent, to&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:40.95pt;text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VStock Transfer, LLC</font></div><div style="padding-left:40.95pt;text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 Lafayette Place</font></div><div style="padding-left:40.95pt;text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woodmere, NY 11598</font></div><div style="padding-left:19.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E-mail&#58; young&#64;vstocktransfer.com</font></div><div style="padding-left:19.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Young Kim</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For any notice delivered by email to be deemed given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the next Business Day following such email, unless the recipient of such email has acknowledged via return email receipt of such email.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) If to the Holder of any Warrant Certificate, to the address of such Holder as shown on the registry books of the Company. Any notice required to be delivered by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding any other provision of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice shall be sufficiently given if given to the Depository (or its designee) pursuant to the procedures of the Depository or its designee.  To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 20. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Supplements and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Company and the Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global Warrants in order to (i) add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants, (ii) to surrender any rights or power reserved to or conferred upon the Company in this Agreement, (iii) to</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> cure any ambiguity, (iv) to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, or (v) to make any other provisions with regard to matters or questions arising hereunder which the Company and the Warrant Agent may deem necessary or desirable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, provided that such addition, correction or surrender shall not adversely affect the interests of the Holders of the Global Warrants or Warrant Certificates in any material respect.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) In addition to the foregoing, with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority of the shares of Common Stock issuable thereunder, the Company and the Warrant Agent may modify this Agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Agreement or modifying in any manner the rights of the Holders of the Global Warrants&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that that (i) if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall also be required and (ii) no modification of the terms (including but not limited to the adjustments described in Section 11) upon which the Warrants are exercisable or reducing the percentage required for consent to modification of this Agreement may be made without the consent of the Holder of each outstanding warrant certificate affected thereby&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no amendment hereunder shall affect any terms of any Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the Warrant Agent&#8217;s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed amendment complies with the terms of this Section 20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No supplement or amendment to this Agreement shall be effective unless duly executed by the Warrant Agent.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 21. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns hereunder.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 22. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Benefits of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant Certificates and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement&#59; but this Agreement shall be for the sole and exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 23. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement and each Warrant Certificate issued hereunder shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to the conflicts of law principles thereof.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenience forum.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 24. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A signature to this Agreement transmitted electronically shall have the same authority, effect and enforceability as an original signature.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 25. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Agreement&#59; provided, however, that if such prohibited and invalid provision shall adversely affect the rights, immunities, liabilities, duties or obligations of the Warrant Agent, the Warrant Agent shall be entitled to resign immediately upon written notice to the Company.</font></div><div style="text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 27. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. To the extent any provision of this Agreement conflicts with the express provisions of the Warrant Certificate, the provisions of the Warrant Certificate shall govern and be controlling.</font></div><div style="text-align:justify;text-indent:14.4pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary contained herein, the Warrant Agent will not be liable for any delays or failures in performance resulting from acts beyond its reasonable control, including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest.</font></div><div style="text-align:justify;text-indent:14.4pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 29.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The parties hereto acknowledge that there are no agreements or understandings, written or oral, between them with respect to matters contemplated hereunder other than as set forth herein and the Warrant Certificates, that this Agreement and the Warrant Certificates contain the entire agreement between them with respect to the subject matter hereof and thereof.</font></div><div style="text-align:justify;text-indent:14.4pt"><font><br></font></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Fees&#59; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As consideration for the services provided by VStock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay to VStock the fees set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  If the Company requests that VStock provide additional services not contemplated hereby, the Company shall pay to VStock fees for such services at VStock&#8217;s reasonable and customary rates, such fees to be governed by the terms of a separate agreement to be mutually agreed to and entered into by the Parties at such time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Service Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;&#59; together with the Fees, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Company shall reimburse VStock for all reasonable and documented expenses incurred by VStock (including, without limitation, reasonable and documented fees and disbursements of counsel) in connection with the Services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that VStock reserves the right to request advance payment for any out-of-pocket expenses.  The Company agrees to pay all Service Fees and Expenses within thirty (30) days following receipt of an invoice from VStock.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Company agrees and acknowledges that VStock may adjust the Service Fees annually, on or about each anniversary date of this Agreement, by the annual percentage of change in the latest Consumer Price Index of All Urban Consumers United States City Average, as published by the U.S. Department of Labor, Bureau of Labor Statistics.   </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Upon termination of this Agreement for any reason, VStock shall assist the Company with the transfer of records of the Company held by VStock.  VStock shall be entitled to reasonable additional compensation and reimbursement of any Expenses for the preparation and delivery of such records to the successor agent or to the Company, and for maintaining records and&#47;or Stock Certificates that are received after the termination of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Record Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify;text-indent:14.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Brian M. Strem, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Brian M. Strem, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;   President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VSTOCK TRANSFER, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Young Kim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Young Kim</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;   Compliance Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><div id="i432860a3a2c8486d8b8af94ed272555d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annex A&#58; Form of Warrant Certificate Request Notice</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WARRANT CERTIFICATE REQUEST NOTICE</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To&#58; VStock Transfer, LLC, as Warrant Agent for Kiora Pharmaceuticals, Inc.  (the &#8220;Company&#8221;)</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned Holder of Common Stock Purchase Warrants (&#8220;Warrants&#8221;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;padding-right:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Name of Holder of Warrants in form of Global Warrants&#58; ___________________________</font></div><div style="margin-bottom:12pt;padding-left:54pt;padding-right:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants)&#58; ________________________________</font></div><div style="margin-bottom:12pt;padding-left:54pt;padding-right:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Number of Warrants in name of Holder in form of Global Warrants&#58; ___________________</font></div><div style="margin-bottom:12pt;padding-left:54pt;padding-right:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Number of Warrants for which Warrant Certificate shall be issued&#58; __________________</font></div><div style="padding-left:54pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any&#58; ___________</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Warrant Certificate shall be delivered to the following address&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;______________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;______________________________</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"><img alt="image_1.jpg" src="image_1.jpg" style="height:29px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned hereby acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</font></div><div style="padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;SIGNATURE OF HOLDER&#93;</font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of Investing Entity&#58; ____________________________________________________</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Signature of Authorized Signatory of Investing Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; ______________________________</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of Authorized Signatory&#58; ________________________________________________</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of Authorized Signatory&#58; _________________________________________________</font></div><div style="padding-left:36pt;padding-right:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; _______________________________________________________________</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 1-A and Exhibit 1-B&#58; Form of Warrant Certificates</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Attached</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our initial warrant set up fee will be $2,500 for each series of warrants, which shall include review applicable agreements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and documentation and set up of applicable register and journal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Maintenance Fee</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our monthly maintenance fee is calculated based upon the number of record Holders of the Warrants&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 1-99 shareholders $99 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 100-200 shareholders $150 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 200-300 shareholders $299 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 300-500 shareholders $399 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 500+ shareholders $749 per month</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If escrow services are to be provided for the collection of exercise payments the following is our monthly maintenance fee&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 1-99 shareholders $199 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 100-200 shareholders $250 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 200-300 shareholders $399 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 300-500 shareholders $499 per month</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Monthly Maintenance of 500+ shareholders $849 per month</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service Fees</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Per Warrant Exercise $45.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Issuance Per Warrant $35.00</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Replacement of Lost or Stolen Warrant $50.00 (paid by registered Holder)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Lost Registered Holder search (if needed) $5.00 per Registered Holder per search</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Escheatment (if needed) $50.00 per Registered Holder</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Other Costs and Excluded Services</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The company will be billed separately at cost for certain out-of-pocket expenses such as postage and courier fees.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The above services and fees do not include services in connection with stock splits, reverse stock splits, and &#8220;deep search&#8221;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and associated escheatment&#47;lost property fees. They do not include services for DWAC set-up ($499), maintenance ($150)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">issuances ($75) or withdrawals.</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>exhibit991-pressreleasejun.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibcc049d3dbf94be08c0c8bb0b18f675b_1"></div><div style="min-height:76.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:10pt;text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Encinitas, California--(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX) (&#34;Kiora&#34; or the &#34;Company&#34;) today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions and offering expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offering is comprised of (i) 1,447,628 shares of common stock, (ii) 3,908 shares of Series F Convertible Preferred Stock, (iii) 5,000,000 Class C Warrants with an initial exercise price of $1.10 per share and a term of five years following the initial exercise date, and (iv) 5,000,000 Class D Warrants with an initial exercise price of $1.10 per share and a term of one year following the initial exercise date. The price per share of common stock, Class C Warrant and Class D Warrant is $1.10. The price per share of Series F convertible preferred stock, Class C Warrant to purchase 909 shares of common stock and Class D Warrant to purchase 909 shares of common stock is $999.90. The closing of the offering is expected to take place on or about June 6, 2023, subject to the satisfaction or waiver of customary closing conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladenburg Thalmann &#38; Co. Inc. is acting as sole book-running manager in connection with this offering.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of common stock, additional Class C Warrants to purchase up to 750,000 shares of common stock and additional Class D Warrants to purchase up to 750,000 shares of common stock, solely to cover over-allotments, if any, at the public offering price per share of common stock, Class C Warrant and Class D Warrant, less the underwriting discounts and commissions. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-271699), which was declared effective by the United States Securities and Exchange Commission (&#34;SEC&#34;) on June 1, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A preliminary prospectus relating to the proposed offering was filed with the SEC on June 1, 2023 and is available on the SEC's website located at http&#58;&#47;&#47;www.sec.gov. A final prospectus relating to this offering will be filed by Kiora with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at http&#58;&#47;&#47;www.sec.gov or from Ladenburg Thalmann &#38; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus&#64;ladenburg.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (OPRA). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a chemically cross-linked form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:76.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements relating to, among other things, Kiora's expectations with respect to completing the public offering in a timely manner or at all, the anticipated use of the net proceeds of the offering, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact</font></div><div style="margin-top:3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Francina Agosti, Ph.D.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(617) 546-0742</font></div><div><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">francina&#64;reportablenews.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>exhibit992-closingpressrel.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if3465002abc74eef835ea16dfdf4c7f0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit 99.2</font></div></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#26282a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encinitas, California--(Newsfile Corp. &#8211; June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX), (&#34;Kiora&#34; or the &#34;Company&#34;) today announced </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full exercise of the underwriter&#8217;s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The offering was comprised of (i) 1,447,628 shares of common stock, (ii) 3,908 shares of Series F Convertible Preferred Stock, (iii) 5,000,000 Class C Warrants with an initial exercise price of $1.10 per share and a term of five years following the issuance date, and (iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 Class D Warrants with an initial exercise price of $1.10 per share and a term of one year following the issuance date.  The price per share of common stock, Class C Warrant and Class D Warrant was $1.10. The price per share of Series F convertible preferred stock, Class C Warrant to purchase 909 shares of common stock and Class D Warrant to purchase 909 shares of common stock was $999.90.  </font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ladenburg Thalmann &#38; Co. Inc. acted as sole book-running manager in connection with this offering.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The securities issued at closing include 750,000 shares of common stock, Class C Warrants to purchase up to 750,000 shares of common stock and Class D Warrants to purchase up to 750,000 shares of common stock, issued upon the full exercise of the over-allotment option. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-271699), which was declared effective by the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on June 1, 2023.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering was filed by Kiora with the SEC on June 2, 2023. Copies of the final prospectus can be obtained at the SEC&#8217;s website at http&#58;&#47;&#47;www.sec.gov or from Ladenburg Thalmann &#38; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus&#64;ladenburg.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (OPRA). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a chemically cross-linked form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to news releases and SEC filings, we expect to post information on our website,&#160;</font><font style="background-color:#ffffff;color:#2f5fab;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.kiorapharma.com</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">,</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, the anticipated use of the net proceeds of the offering, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Contact</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Francina Agosti, PhD<br>(617) 546-0742<br></font><font style="background-color:#ffffff;color:#2f5fab;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">fagosti&#64;reportablenews.com</font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>kprx-20230602.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f796ffe8-0968-4b06-824b-cd8ddbf679af,g:827eae95-d350-4afc-a6a2-d753c070e75d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20230602" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20230602">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230602_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230602_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>kprx-20230602_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f796ffe8-0968-4b06-824b-cd8ddbf679af,g:827eae95-d350-4afc-a6a2-d753c070e75d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_850040b5-f14b-4bbe-8c49-35f23f4f3b6c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_18d88b0d-006f-4bae-8597-26f57b1e9183_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8e5c9fb8-97ee-43a8-bdea-f81d0f150995_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b89a051c-6eda-4df9-b71c-73b99f2b02f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2b9041b7-f688-442d-a09d-c6ebde292068_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f4c78e60-ba07-4c01-a2f9-1078a4e09259_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3d533cb6-10fe-4beb-a941-efed769b1fe6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_159d9275-3bf4-4920-b56c-9605dbcdf157_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bb76a7a1-ca4e-45c9-b9ba-de6be8729968_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cc26998a-8e46-4063-88da-8215dfa8b57b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7622bd4f-904d-4bf9-8b20-46bf8f668a59_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cefe1a7b-c2ed-4a73-bf3b-230efb795317_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_87424799-fe5f-4456-917e-6bebf2712835_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1d34475d-a648-4824-ac52-43663f7f2424_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2a9d91a3-5a45-4a70-b361-791807de6377_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d5972434-fdc7-44a2-ba64-09c7345563c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a1ed7a6f-9d12-46af-afc5-5bcbbbd35b36_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2cdfd770-92ae-462c-b2d3-0611a9327125_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ffa81e6d-95cf-49db-9147-068b655a8efb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3dd0c2da-08cd-424e-8f75-74bdd708f41a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c8b8e388-0e55-4b37-ab51-6290f99d2d45_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_345a3382-95b4-4c8f-89c9-08ee61c45fc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8db5da96-469e-47e5-b071-f27501a8985b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_30141ce7-4745-45eb-a236-99ea2def206e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>kprx-20230602_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f796ffe8-0968-4b06-824b-cd8ddbf679af,g:827eae95-d350-4afc-a6a2-d753c070e75d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20230602.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0d762d1a-1e7e-47e3-b4b0-03c9f8583d99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_DocumentType_0d762d1a-1e7e-47e3-b4b0-03c9f8583d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_89ed200d-ad79-4d40-a039-84d0ff7df67c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_DocumentPeriodEndDate_89ed200d-ad79-4d40-a039-84d0ff7df67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_844ff5ed-bc50-47a5-b801-f2235a01a5fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityRegistrantName_844ff5ed-bc50-47a5-b801-f2235a01a5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0315d65f-792f-4fd1-b86d-cda5ec7dfac1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0315d65f-792f-4fd1-b86d-cda5ec7dfac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3c825f87-df13-4b92-836a-cc90d19637e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityTaxIdentificationNumber_3c825f87-df13-4b92-836a-cc90d19637e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_04a99f86-49be-4474-a375-90162e6faa8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityFileNumber_04a99f86-49be-4474-a375-90162e6faa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_520b900f-9547-4c7e-a131-d375529fb3c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityAddressAddressLine1_520b900f-9547-4c7e-a131-d375529fb3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2b415a4e-7d70-458b-aa45-4afa08c703d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityAddressAddressLine2_2b415a4e-7d70-458b-aa45-4afa08c703d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b5b3e51f-5915-4a95-b8c4-e361e33e9e10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityAddressCityOrTown_b5b3e51f-5915-4a95-b8c4-e361e33e9e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_61ac8ff5-2e5e-44ad-bad8-f2be2bd23e5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityAddressStateOrProvince_61ac8ff5-2e5e-44ad-bad8-f2be2bd23e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c91fb71a-6e5e-498f-a9a9-683935055aee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityAddressPostalZipCode_c91fb71a-6e5e-498f-a9a9-683935055aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b89fac70-e164-45bd-9e2d-9753c7ec8d1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_CityAreaCode_b89fac70-e164-45bd-9e2d-9753c7ec8d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5b670a45-a93a-42c5-8a42-08d7c6c38df8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_LocalPhoneNumber_5b670a45-a93a-42c5-8a42-08d7c6c38df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b64d55c9-c7e1-46c8-97d9-d39b2bf5a081" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_WrittenCommunications_b64d55c9-c7e1-46c8-97d9-d39b2bf5a081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_967643ea-ce72-4852-96a4-3959d6a39dbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_SolicitingMaterial_967643ea-ce72-4852-96a4-3959d6a39dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0dea5713-cf54-4885-a47b-8140e98f226e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_PreCommencementTenderOffer_0dea5713-cf54-4885-a47b-8140e98f226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3ca1e8ef-c52d-4077-a222-2b672919fd5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3ca1e8ef-c52d-4077-a222-2b672919fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d0e29495-4644-4a3c-8aee-a97544f5ec05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_Security12bTitle_d0e29495-4644-4a3c-8aee-a97544f5ec05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7de2de6a-9325-479b-a9a1-3572e2dd4b30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_TradingSymbol_7de2de6a-9325-479b-a9a1-3572e2dd4b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d9b1159-e3fb-4739-a9a5-0e515e097b4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_SecurityExchangeName_9d9b1159-e3fb-4739-a9a5-0e515e097b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7e65aae0-fb91-4f52-a927-4a9b9835cba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityEmergingGrowthCompany_7e65aae0-fb91-4f52-a927-4a9b9835cba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_07e11241-c1df-476e-8273-a9705636b507" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_EntityCentralIndexKey_07e11241-c1df-476e-8273-a9705636b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_493ef589-07dd-4bbd-a6ee-3ae40411305d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_AmendmentFlag_493ef589-07dd-4bbd-a6ee-3ae40411305d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4ebc5beb-7d8b-4e92-a7a0-b923a8284340" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dffb2742-4329-4d5d-8b20-3e1907456538" xlink:to="loc_dei_CurrentFiscalYearEndDate_4ebc5beb-7d8b-4e92-a7a0-b923a8284340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #J8   "7" (   !"NIPN   '_$E$051X7NW:
M(0$   C ,/J7!D^"BTT^PV<!            @+#Y 0             HL?P"
M            0)KE%P            #2++\             D&;Y!0
M     ( TRR\             I%E^ 0           "#-\@L
M:99?             $BS_ (           ! FN47             -(LOP
M          "09OD%            @#3++P            "D67X!
M    (,WR"P            !IEE\             2+/\ @           $":
MY1<             TBR_             )!F^04           " -,LO
M         *19?@$            @S?(+             &F67P
M  !(L_P"            0)KE%P            #2++\             D&;Y
M!0           ( TRR\             I%E^ 0           "#-\@L
M        :99?             $BS_ (           ! FN47
M -(LOP            "09OD%            @#3++P            "D67X!
M            (,WR"P            !IEE\             2+/\ @
M     $":Y1<             TBR_             )!F^04           "
M-,LO             *19?@$            @S?(+             &F67P
M          !(L_P"            0)KE%P            #2++\
M    D&;Y!0           ( TRR\             I%E^ 0           "#-
M\@L             :99?             $BS_ (           ! FN47
M         -(LOP            "09OD%            @#3++P
M  "D67X!            (,WR"P            !IEE\             2+/\
M @           $":Y1<             TBR_             )!F^04
M      " -,LO             *19?@$            @S?(+
M &F67P            !(L_P"            0)KE%P            #2++\
M            D&;Y!0           ( TRR\             I%E^ 0
M     "#-\@L             :99?             $BS_ (           !
MFN47             -(LOP            "09OD%            @#3++P
M          "D67X!            (,WR"P            !IEE\
M    2+/\ @           $":Y1<             TBR_             )!F
M^04           " -,LO             *19?@$            @S?(+
M         &F67P            !(L_P"            0)KE%P
M  #2++\             D&;Y!0           ( TRR\             I%E^
M 0           "#-\@L             :99?             $BS_ (
M      ! FN47             -(LOP            "09OD%
M@#3++P            "D67X!            (,WR"P            !IEE\
M            2+/\ @           $":Y1<             TBR_
M     )!F^04           " -,LO             *19?@$            @
MS?(+             &F67P            !(L_P"            0)KE%P
M          #2++\             D&;Y!0           ( TRR\
M    I%E^ 0           "#-\@L             :99?             $BS
M_ (           ! FN47             -(LOP            "09OD%
M        @#3++P            "D67X!            (,WR"P
M  !IEE\             2+/\ @           $":Y1<             TBR_
M             )!F^04           " -,LO             *19?@$
M       @S?(+             &F67P            !(L_P"
M0)KE%P            #2++\             D&;Y!0           ( TRR\
?            I!UY3U6@7,IX<P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   M     =" (    ,W,R(    "7!(67,  &ZZ
M   $=0'?_#1@     DE$051XG&*DD2L   "5241!5.W600D , S P/HWO:H(
M@W*G(,_, P"(S>\  . ^PP$ Y P' ) S' ! SG   #G# 0#D# < D#,< $#.
M<   .<,! .0,!P"0,QP 0,YP   YPP$ Y P' ) S' ! SG   #G# 0#D# <
MD#,< $#.<   .<,! .0,!P"0,QP 0,YP   YPP$ Y P' ) S' ! ;@'_ELF.
0Y"-O70    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140136935811536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>kprx-20230602_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20230602.xsd" xlink:type="simple"/>
    <context id="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV8yLTEtMS0xLTQxNDgx_9706388e-1fbb-4171-b38d-c934fb99b890">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV8zLTEtMS0xLTQxNDgx_c8bfa458-b23b-4770-8b2d-9a3526fa217b">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl80L2ZyYWc6MDI5MjQwMjAxOTMxNDZkZGE2OTJkZTU1NjRmYjU0MTcvdGFibGU6MTY2YzNlY2IwMzY5NDRlYWJjMGI5OWEzOTU4OTg2ZjkvdGFibGVyYW5nZToxNjZjM2VjYjAzNjk0NGVhYmMwYjk5YTM5NTg5ODZmOV81LTEtMS0xLTQxODY2_df855593-0f56-4c07-996c-12954cf6f638">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA2_07842d17-1475-4c91-97a1-a8b498638954">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8yMjM_e9ebf55a-f465-41d5-83cc-9e261a831de7">2023-06-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzAx_d338e59d-6d69-4f0d-9fa9-b27674a4821f">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzEx_1099fa65-df92-4762-9d81-5cf081b33fbb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NjY5ZDhlZDQyN2Q3NGUzNjkwODIwMDY0NmM0OGM0NDMvdGFibGVyYW5nZTo2NjlkOGVkNDI3ZDc0ZTM2OTA4MjAwNjQ2YzQ4YzQ0M18wLTAtMS0xLTQxNDgx_8e76007b-553b-4ca2-a601-776e454b536c">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NjY5ZDhlZDQyN2Q3NGUzNjkwODIwMDY0NmM0OGM0NDMvdGFibGVyYW5nZTo2NjlkOGVkNDI3ZDc0ZTM2OTA4MjAwNjQ2YzQ4YzQ0M18wLTEtMS0xLTQxNDgx_66585429-6644-454c-b447-b1d494c9c7b6">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzEy_b9ca2e7b-5466-4e70-8ff0-bf179f174265">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzE0_0f07b230-6f87-4dd7-807d-ab00195e3692">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzAz_b69d8c41-7745-4ccb-be1a-d5b09feb3a2a">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA0_81491789-28c9-478f-8edc-37ab6842f82b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV80MTQ_b48c3f8c-ea9e-433b-aaf6-b3648eedd8b8">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV80MTg_895298ec-0936-4376-9f18-6aab32765d33">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA5_a9484b7c-44c5-4414-aed2-0f155cbb285a">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV8wLTAtMS0xLTQxNDgx_48b9eff7-345c-49d3-ae04-eeebb55160ad">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV8yLTAtMS0xLTQxNDgx_be16e4c4-ef07-4f61-8754-eda57a83b4ff">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV80LTAtMS0xLTQxNDgx_36f6d5e8-a6c6-4070-91ad-32f8240aecf0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6NDlmNTIyMjZmNzgxNDdmM2E4ODYxNWIxZDRkZTJmMTkvdGFibGVyYW5nZTo0OWY1MjIyNmY3ODE0N2YzYTg4NjE1YjFkNGRlMmYxOV82LTAtMS0xLTQxNDgx_3163448f-77c1-452b-93d9-fd5179622e4b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTAtMS0xLTQxNDgx_755fd0fc-0fcc-49c7-97a9-16b7a0650972">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTItMS0xLTQxNDgx_d8a43bae-4a50-4c07-8fe5-d331d99e3d84">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGFibGU6Yjc4NGNlMDZkMDJjNDk1NjlkNzI5MmM1ZDU1ZGRlOWEvdGFibGVyYW5nZTpiNzg0Y2UwNmQwMmM0OTU2OWQ3MjkyYzVkNTVkZGU5YV8xLTQtMS0xLTQxNDgx_b6331edb-bb13-4a4e-ace2-395285bf88d1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMzA1_1983f948-ba73-42d3-8ba2-88df07bc5f72">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6fee30e10c884b2d94776074527e9e32_D20230602-20230602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjMzMxOTExNDA0NjQ5YWNiMzNjNTdjMTgxMmY5N2JiL3NlYzozYzMzMTkxMTQwNDY0OWFjYjMzYzU3YzE4MTJmOTdiYl8xL2ZyYWc6Mzg1OTg5ZDQ4ZmI4NDhkZjg1ZjBhZjY2MDEyN2ExZTkvdGV4dHJlZ2lvbjozODU5ODlkNDhmYjg0OGRmODVmMGFmNjYwMTI3YTFlOV8xMDk5NTExNjI5MDk2_1983f948-ba73-42d3-8ba2-88df07bc5f72">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;7Y^NN8,#,P^ />72IGWAMWK%Y]J!G\#4$L#!!0    ( (F&QE:?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( (F&QE8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ B8;&5L]7
MZ;#O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ B8;&5IE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ")AL96CF*/:WP$  "V
M$0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ B8;&5I^@&_"Q @  X@P   T              ( !P P
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ")AL96EXJ[',     3 @  "P
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52P4&      D "0 ^ @  %!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20230602.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="kprx-20230602.htm">kprx-20230602.htm</File>
    <File>exhibit11-underwritingagre.htm</File>
    <File>exhibit31-seriesfpreferred.htm</File>
    <File>exhibit43-warrantagencyagr.htm</File>
    <File>exhibit991-pressreleasejun.htm</File>
    <File>exhibit992-closingpressrel.htm</File>
    <File>kprx-20230602.xsd</File>
    <File>kprx-20230602_lab.xml</File>
    <File>kprx-20230602_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kprx-20230602.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 25
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "kprx-20230602.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20230602_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20230602_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20230602.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20230602",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230602.htm",
      "contextRef": "i6fee30e10c884b2d94776074527e9e32_D20230602-20230602",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230602.htm",
      "contextRef": "i6fee30e10c884b2d94776074527e9e32_D20230602-20230602",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001372514-23-000097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-23-000097-xbrl.zip
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M9^B7LN&Q23L/#I,+T'8QVT#Z/&3S2+O.*BW5/1F I&Y=11B"C[T33*)Y4H%
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M(K;MI]<Y*(F;#&2S*&JP\MX7*+EX^AN']<4+UV'="LY&!.?B[>70)"?)X.A
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M.GES_HDO,3#5<+!WL$&UX&V"PP,]4]V*0NSV3>J)O2!XJF?$*-H9C" <[KW
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MVZ:I 8BRP5L7&]7#[Q8*^RL&O .B'V-URB=TKYX3VMA5O&R$6US5R),GB@6
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MANOIE*)SDH[X+</C.*5RA_,[]OC>2*&")+7/;,O936<JKA*)<GL(4>DVNS0
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MW[K'V&DVZ3TL@?8^*1ZD^;E;9NE*GW0&[AB3;0?E H[O&9/4B(IS^-@GHN+
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M#+:SH_SA:&SB4(VFU@W>.V+_H72$(>VVX7LI$18D)S/ 6X0-C,.&I1C&;2*
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M^&A?YUCWNF-;R#'FX>9*HTL:JV,[+5!:L5!B3;H(Y)[@;D=[GX9)N,S<DW'
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MBYJO!*E<NG-V'S*=ABMR#$8207MZ>B^@MP;"" >*/,8$UHSCI\D:=8\=T[T
MZP 7K%#8O\4);-PP] 9G&P&$7J,%YU>3'!8=*=C8D:6;$%;)NPVN9R@&%V%\
MG/2[Y'&R+(?#WO R.!A2M_/835087)3;M*'IU9EJ2K??#H*#M37"!]T3UIG3
MX>C,EWLO#I;KS'>$2Z4,N& (3K@T2SK6/@I0"GZT/,#"5(2FJ;7N32W-;9SN
MV;;KQ4H8BL]XZN1"\#+*>\#+ZR:3$IQQDWZKIMY+H5PC!J&&AYYA)THJ(GG"
M6^AF.%MH96:.EN=2L>_(3>)_8:PD0KPT<>2F00$^F$;S@]'AAI!-\598U@KE
M=KP7X*='MMO='$,GDU^^>F%[94@KMDMD(JEQ$+'B3A,OGW>GJ?QN&66NN^P%
M]5PLB4M-5$)A,=M.DL,+3WA;W#ZB;?$3=@>S&\&T&1GP@=(5I,Z=YFK4 [>1
M\^Y[39;Q9YZ,!R/\Q: 3=C_],I!TJW1-ML$-?6H:\N.?*<J?VY(:G1B_5(A[
M4<$5MZL>_J0W!CZ$^?_LG9+?9T*2S%C(?D:5*6:KX*B9$/WLL_]-;,RSO# &
MF%>VBWPD)J@T22.NT[W+*U/4:QK>5?=PQ\6N?__#C@=4.26*_JQU%9=I;8@/
M<7O =>S_7R0;VRFLC97][%G57GG)\5N<V91K#:?@?6, @.BR)>DD3<')[R(J
M&ET?\;5>[^F>O,EP3MY7>T<KCMY?\TPM@C<1?;1YLB:T/?MCY9V%P,0[G\5.
M(-TA]V >B8I&V86@L%$B-P2!(;)=%QU@NP!W\7B<DF,WX?%I_^S:;61Z:7Z_
MS>BZ&=VC;4;WZ\ZPL2Y?[#<\*"OY,U(!J5$!A"NN*TD9K20E=^&!\%HILU&F
MBT?0F+ZI_."?]QO- UC$&6-DT#L0YI3W!I6#)VJ.7CA6\D@RJR[HZ/89 &Y0
M*85NU3G\*H]->$K#@QC1DZ=W'3';1ABK"T??.8MH'PBXR44T/:0*S *=GK"Q
M\,=C,A;.J.+B7?!_,78"WV41'(4#J6%9UH4[]1,4E@5=XE)_>N_C8/%@IRF'
MC+_YC-CTU*$<OZ9M<+O1>CV:3<]E+A^GS][DDP^[O\V#$]W@IE6OX36$@6U%
M]-A$Z9$7U%*Z%R#0U;3.[1!['Q6&\<F=(,:_^7R2/E6OUYF,$G6-.91'@%$U
M 3]+DZX0&3J.^0GOZ _#V=&K*T6HE?>);4D^^+T,9Z+)R.CMIP^/,9P57/R*
M(05%;"G/_G?3@V_>'%D$3;V:$Q7X@CW<@Q$V\[.4.CUY^%Z<#MW+EA7X[=A%
MCVC=XC?0)F!.%-\ELH?]<#@]Z_SGJ[]FU5]TKGJP29%+,(J":(4BT\Q(S+[;
M%K '2%1W$,K'.13^W^?@5=Y%*=?RE6S>H0*EVDHGS6B%#8LKN32:PC2>N&&-
MY5Z_J_GH56PZ'!6[VFAZ)V:!B$=P:GO/;;I*#UT'IQ.>=*^5PONXQB)^]AW^
MK8QYTQ63B56:<(VJ87;WU R(+6@9R=(1.$XAFC"R;01L7TZP21"=LFCBGKJ,
MH<A0R6N^.ETK6S$W_Q,V,V;#V0-'*_= NPOEI@V-V\[6F D;_T5"!-)3789=
MXCELNU-8S-@M=^.PS;I,6X1)1* JN(U$0'XU,?8]3>MS3:X'R)?NP5RVGUF0
M4XY ,1HM*WAKV:.X$^]Q/M/A/WV/CM<3M@C;MBPJQE&FRMUW'U-E4I&'^_N'
MMA"TUOCX.KVQ[=ND.Z>-#;5JR]V?RXB:C8Y/-% 0:X'DZ.H?O,R4*KEIIDRK
M#=LBZTI1Z;EM%K''8!EF'M[OLU]^G5<,+C)# Q5:9"2V*_K#, %VK;C %WKG
M@8C*90X<[@7G]=MOO&RD3U=19L-1E"O]L=,%[FYI];!1%2DE :-D!SO;7!-R
MU<6KFMX5&'R?W'J%=[AAT.$ 2:-*#5M6&F7-ZA1K-#<#@.8;-^Y0J<EM!G-P
MLY (R QY^HJ@I/P]=N]0U7U>?"B1]ZF(,<"!);;3BO\51U7D5DL*UCC2Z52G
M R13R\%J6,@?\JMAMYN$/KV#':=#/V2@W":P5=$W6_ ]J1\ZQYDX8NNQ5B78
MD Z327.==W7>K1%('W00_>):T!,\%6?PZD,(H3-,?;'3>2PU:DO=1D-86#I-
MZ/@/+>ZM@R*=VF4);$%:23ALR6O0'S/2=)V-A+3R()T=,\VM")NM$[K?$X-]
M8FZGZ]23IU)*YZ>#X)H_ZOC&L"G&M!EZ0Q=>>L)).#23%7X)LDE9A,RZB*A
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MQ)R&GW?.=Q(!VQ0@ISPJ+V?(VXB8#80#0>]QCEQ)I#0/%6=SE!-_.B775<.
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MW"VJ<[ 7U$?\?])&0)^>TGZ M8ZG,]HR^'F:_%4GD=I"N!GB+.1;(LCF<!F
M&)R#ILBW@"R<XP[AET"OLWHZABT!OY#[!G=4E50U=1;;E#;4 [!G8;&X!Q5J
MFOG$5Z_G?3ZEC8(/?#N;):F4NHGS4\3JR'<WD._-Z@(.'G0:;WUSW*LYGO
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M 8UVKV<<5U=#DHO;//9.J[SR9 8*-<Q+1#A)BL3C QQ[9ZWS(YQRF]C,U^<
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MA<HO,2WNKQH/V05G5Y_#-L14@[4K%EV>,3MOVL7,1X*  M#,=F2I(>T;%4Q
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M-'FVBM-$&4!.O\DZMMT)^2ES[Y0#V&87LG'Y/_?Y1^^WKVR.SASJ2UM302*
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MQ4D_\%&7XY$KACL;B.BFU HA#V6J]& R58"RJ@GPDD0!(>>XEIL/Z2 KW#N
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MVMT=)M"!;#$;>Q.OYJF7?5]SQKA6L0>V]7RH&^^AD7-8AE[@M7[CD1RWZ&7
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M%]&E RG)S:MKB*4G@$;E"05BB)]3^PYH&SD+M454DG3GBRK/]*QFU6K:4IC
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MNOSB=3?5A+V:)5G4)(B*088%#KAB';>=#B8ZEWF@<I?25FCV"\1![Q%VKCL
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M\BN,5-?B61><B,+'_1IM$C)]'S+SS/.Q1A?>&E[\&3TL))AW&VH($-'=I%9
M+"$W3A=FJG.\1>H[1;E800XR/*\<F!>W>[5YAH;@,=JFT4@QV!I,Q2!\--]7
M24W>RFN!*C=NI6>W-*GNU(EUFQ)JPBSC3^M"LCKZF#-J(2V2IM,"HM$M5_M8
MYMH>]6Z+06N!-JBHG$8@WKP,]4VX;LT><,/>%V-5 -Q(^N[W.!&\D=4']\L\
MMZ1/),6.'AZ-)5.K@+PAABZ86 HZW .>+MR80H-^D(^@TD%O[Q/NVAL<W#UX
M^T!XK[K9 ^.>9\Q3Q95[UC;!'+?;7<$4C%$G<EL^QMXI>B;<,U"S>.4UN%/?
M:_?T=7+E$'O1314!-XQ91$K@C;B Q\+\1?8*:R"DZSYG]Q=INTM*7Z GG:-1
M!$-JQ S]Y'L@ 83A($,O9-WP%QH6X X?WJ@%DY#;/>0\4PONPCC50!W-!R)8
M;B5FXD:MP,HN.:='UC5E4%4FG%7(8^ ZO62""G*'7]]A2ZXZ"5=TP^V*7>1)
MI#;9.&U;L&?9:V8HJ"8R.B"^L;WM:+FUV(HV<#?_JZH_1D=H!>(@:*X2?XIH
MH(H'2DW;_6]- V5MNG_VEZ A993_9T %V;3^, B.9'R*&[XG["7W)A0T(5>
M;%1=62=,C>( 6X$!]P=%$;D>4!I;MT>Q?"=P<RYW1%"^:0[MHO.IVS'/S^33
M">&6Z(Z5YYN%FK4O#YYN[1Y<SSB\N7.PM7>7+'',^MO_]]M9)]&#>1>:F^&T
M=&@"[NC-?H3]ED0?L!(B2=6*$BQ-'+TMTT? W,@!<R.2HKV]W>@8G8V\3=!_
M6!7J GR(.#I=Y:!J=[9W[\->,&\01T>'T8O=[=W]>S%L.H98Y4R;ME:+;[]^
MNO_J(^[L)6WL+3C([L.;'+8M\XQ&W]=Y@J$L>)E/&?CMSY\[>N-?"6C-_:BE
M\L(&PY"!E("-YLS51\N#GI/OP0YMHF^_W@,Y^$E=Y"6"U7[ZZ<-]&/O.[D'T
M _R=1%>U]V'(WX/3@.;OSX?1]N[.SO9]&+.K\NJE@DW2DLZ;HNC V7/_%-Y)
M-06'+/I [_)%M_>?8ZN_N%,:W^N-]6[KHNM,]D&&SUM,W_XV3<MUTW>G0<%_
M<OI(P_MC4+Q'#^?M=IY'/R6SY$JU<*9^0'SKPWFW7ZLJ6ZA:Q=&[?T4[.P<O
MGM_LW79>;.V9=Y,7V7LZ"M5^5:VP?@,4^P7E W3>\^;J?60O9_7]O_#5HA_S
M_GM\6EKACE[HC61T)69FXV/3JT@M!!W7#?5*5#SVPFVZHIBC5GP'W7Q-(JN]
MF*GNOF(>HI\N8=1^#-#&Q.C9-$2OP@&)1)>Y)(GM-8S[<4G,,  H,5.^0D=.
MO=\]1#Z =!+9<_0&\7Y-)2B!1CT_\DN*-6*ULJR9E)->$=ELE[F(87 B%IT^
MZY[LN>F*M2.5%"@+9CA%@R0RX)/->F,)9G\IJ&H2B2&4X"6&[+M9(T-O@W%8
MGP=2,-E8:1U\!W\?V<#M"NFE4)2+*WF_?"9_D"EYS3D0K*/&P##!IQEP#:YF
MMW4VC#!5V:JV=%+.SSN_QHH038O9&JA[""EBJ[NLM]L8%BGL@!R;=H[,*R!4
M1GE)+')""7*>U*;1JI.FPO^<KJ9-GB''E4:>^[B<)E^L"EA"5:T:I,=&F(X[
MH28[[)0J>VQ"T1'6N,!?3F ^:A*8-YA@?[[YX\--&N]NCS5I?+I:+@N'&OI0
M]S6_XSSR SP)$K_U>;CN S5LK\<]0G%EE9C?EYIL#[<T8X@*0[SP40YD[1]%
M-;5@#P*Y5'7&F%%B2<LR"Z[I]68WC.JN8M!PSJDJU2PW>+$.3J[S8$G%$\P8
M]8&AS_99<(1!EX\M5G-@T1)M\M+/[??IH&/)Q[=52)2G8)^<U]@O:E,D8$;_
MO/I2\A"E*Z%0-O6<..*+"3-+U+6PV#AK+\!=.2Q[[3N]KO2,&D3((5<Q(&2Y
M:;6DA$[?)M((0X0R\#@,S+1WK9"5XE$B381;6NTZHE0XTY5)+U>'6JQ'BCB\
M#:@+4+@%T%WJIF!//PV9C?7*"=;2"K>#VLS \&J(JM'B-S4I9'.S[1,Y,$P/
ML"6USJ:GL]#)/D3+>DJ5\RXWF@=(CJTM0DV)V4EQIM7RCANN-9\*T-1<$)Z/
MJK=I <7]H;*/1?(;%SUHE&R8;]N0#;:=XOCKM\&BRKBS@Z?N.QAZTO29L:N=
M?2IZ$T&'#D\GD\9368<4E]\2D,FCZM^1G!+1X3<19*YV&*=MI/?YW6J;<<[-
MG 'N=SLU4A(,_T+3)9=& -J"C5E(-2"I0LI^*ES)\@8QL>!]8)%#JZ1$UNKE
M'/8DMCPP+B3Z>V@L+!T5PH5WKFYAPL[^S?EV<%ZLNYLNL<1R9;?6@U!::,:4
M5>=]A%>3.FDZ76FPJH2T%'(_J<P&%#0(F1Q/[COGM4?:F;#^Z_4+YCXQHA8M
M4U:V2K43N82OX,Z(IC,#G[&YILMI^V/W5$J((+<SO7Y8@EDX5ZV))^AR0*\U
MEF;);9E,\5';C+8<:MW42)79HQX>LQX&_614KV/QBUIC2Y<"C*2PUF"LI0D*
MU8+K[S4#WE9TV! "1+<#0GIRE0V5[$N9?]-O;N2<$OT@EZYP#/>&]30,4Y%V
M.Z=8LOH.9R Y#%S?:_@LZ+C -LMV^HA8$,&IQH0UL^95B>UN;_TY*W\/JB??
M5:&PR,*(@G>\6%YE4Y$H:0Q:.=UZ)1C3?L!AR9WQAB6EV/".PY"'R(3NQ<'6
M.D93T^(@$!!;6Q B II+^_*\E*+1_GWR6COU*,6F*M-T^P&)<VC@'K#P[HY5
M>+_G]0H(R)W79LU-W\JP>J2T4KUBM\$4+ L%GL-WX2/X?2\_W+DM&-\@@DGJ
M 8^1"' <F%.< @BQ9OCGDL=\$60I<MD2PJ^D=R-Q#3*7@735'MB@(<(E/?R;
M%'\_5@*,LQ+@P2B^O;$JOG\PY@14S$_))>_,_W;(A.Z:Z*Y'XT@QA#4N2->+
M0>@#O2)9BK%N#R :LU\FS9K$I?@A;A]=H4^E:Z8O6'Y!7/"2$C#U[;,B3_DH
MP38GRSHOTQR,WD9'I_^Z#H";3-4]]IS6C"YM+*$Q5":<7GR:).>(ER#*?IVG
MHKZ&,XYN"6V[SQT[=,9,J<&&"!4Q=^K^M(KYH]8(@!Q//OG3ZYQ[!,$+(C^7
M/L-.883PJJ7]WKF3--6K:W51I=3>D8G%&M.WSV7VTKQ1'MN7=9/T&>GS\,DT
M4QR5^8@KHHN2_ LCN<SQZMV:3U"=+Y-),5U5N6L-40>5.770@%=>+1ZP];H_
M5B5^Q&V=L;;UCIVOLV"(V/CJFMW:=%I.G9%;_:X#\]ZW0C*$40-L(J99ZKH$
M=(GE\N+=9=JO!N[65N?,*^=4(J%ABO2DVGXD<C';HO6OJ[P/'0K^OF*54O,6
MEYF:\=15*62F/-=$=VHFU%#/Q?K\=!2Q)K!"2*I=3OOX!ZQC#D:K8Q*BY;ES
M_8*L5<O6!G,0/9VV \$=VYH -C 8BS;'90ZMJI1<HE>6"-(K/*4&[K%0B688
M%0,R=:/3_21\Q]C[7!4W]T*,GVX-52B-4[I/B5&)U<[=2OBO*#871/+9$ -S
MS&?B&L2UVWI9NGLHVXY24![<9]X+IZ/4$_%<O[L0M?[ DU R]#=Z.EPTSZ>Y
M!.4)P[;N]L*CJ&_LO(0=8NN!K+5=H!]D^( U?9[M@2B?V3:7-98KE)*)]A_=
M:(.>K\%?K L9LY>L<[]Q--?$@<R)TAFCTM%AGHKN^P:199K"-"=V%NZ^K6D=
MZ2_";8J\1DZ/J! [8"@RUNM8R6@IHI\V?25A1 PMD-87FF31HP+YY+YDF]M;
M.P^H@<'N>!L8Z'#$'9_;WCZ^3J/8&(I)IBHAF^INS&! -P[BX8*7RF;@&)&F
MW1<# /FG/EG"/;E\ !+^_)Z=Z&_0D8A^3GY3X##<>1*G6T;%69T.)68/'C[8
M1\)OEJ2['F:J0,9]Z:E&A4Q@!$CS68IP=ONQXA:;JBML_)NW7N=QV0).A\(X
MT*(PYEM@D4(%)R$8'S5X:TU+'R,17E43PHR.7.2PCZF;\<>LNN13=Y$4,^E[
M3*V;\0XK;=Y[7VO"^Q4RB\V2U)R%2#=6<=D='/>(ZZ!3BFL1S$3@S10"4M G
MC;(<P1XX%1JPX59;-2W(T[E YMHZ5UB7T5PUK5K@09Q,$=?NW"%&(!N7=.47
M>0'F#L+"'S6':(X76U%TOW3',=A%M1I+#IB<7DU]AXJ!.B6:2EV#2L+2E%H1
MJ,LI_*G9^M;*!X55+#JT'FN,DCDM;A:Z2(30"FZ52*__N[2LLPEF+'15%/B&
M.TA]2S>'[&9=#1@XV*LKF)(6!<D6 2]28I$<ZUZ# @72*(%?2?QS_<#;^NH/
M><ON;=^SPSYZHY34)1Q+:[8[W;-?YN'/PC'BNPT2TR9M<J2(];K1")-!8TNQ
MIE>1D+%LX 72.G6< G8JH[_+J97.L9,0_'7)R4Z93RJJPJRJU<>P$B.=V72N
MLA58G#MWBJ*7<W7\DHB:;@Q2"'9)IV.8,"I++E]$47:[VZ#$: (=:_?,BNG5
M]?)-LCVKI%N2N9]YJL&0.PX- 3_@P(49 $^K9@.$FP40_J#J0$5\"'<"3\$>
MSZUK</!O%JMVQ3W[\(N,NW1A*HN9J,&GJ?3M/EC^8N[&AX7BXQ>Y0[MVH@?Q
MO!V!$/*);Y*X)EB$>X2E:-3SZDSF.+;TS2BGD%XJ0!3V.:S?.V2NVD@F=R@E
MW@3O[F^]H.CX64\/FIY01A4*'J*CZ73;;Q7J5>P87M=$=X;O2DJ3/LL;TZ2J
MT9".1A63H?93VI2Z!XIO#+Z$WIR/=9"/U7Y_K-I/]KS0LS0VT\CI/S+>,!])
MD6(PN QI <$;5NUF-=M<PAW I] Z18)3AA%!L)P5V6NHEMPCCM2%WE*Z=VRO
M7ZPEL'/XY@AJ>%'AG2AP_4]IZGS##@3.L7)OCZ?IF(ZGO?WN\21+3X [&YOT
M?0'J9$LU[>Y!H&6C7'&/&\[I)U,\BPCY %]A:2<QRIC&)AW:(#&P^2YN;3L>
M2%[W+O0T&@3IEM@\L98F7F]A@7_'B[%Z[)=Z"@*GKV@Z.%]J7'*(<)%S19WT
MB*^MF5NOX9>MTRWDC@-K7W?C^PF3!G'T_0I.U)7Y@&Z9@YREN)-N(<P/T/Q*
MQR3?;'[]0GQ5MF-Z(%.MU2,;2K&6=,%V-,C?Y'FSMCA8=[B$>V+7I#KKD73I
MUJY&V7DW[\$WK*5FW37J$%TVB8%S^SU%!;IF=+)AJ*G9V=6_DN+J*Z<A-X^X
MU[4V,1TI.RUC\#8SRNCE%,(7!4]W@>^^_7K_V2O:$/B&7LR?*P-JI?E\,J?/
MT?K%&;^!>4(S8,BHHS&%&;]$,N2QO&X4C7;&G)-Z^R[Z]>W9N^/3T^C7'XY/
MCM^_$72/GQ EI&^:K!K5HUD4]ER/-" QVC:3MFI7*JFEJ1X<S7 S29/>#FM^
M5UOV+I-UX334CV_?GQQ&'WXX//GY\.CXE[.W1X<_G<;1VW='GS*C]V&VO[_R
M6RR,ZZBA$[:A?TOSH9^WN/]0''V8;[T>S/A>)UPC78VA?[]+%LIMP=29A7OZ
M5F=H"/)K1>#2*$S "ICB:)ZK&38M1C8=T&OOF>=FY"]ZC_7 9U-O0?=O]V#W
M"YS%89W^S].S]T<_1F<GA^].WQR?A'NGW)^%NC\*VS33N*U>>+#*^[KV(F-_
M$T]A'Q%W&,5=UVOG3]<ACYY6U_?)L[]]E>_O[3Y_NIWL);OI\_WG3[/GT^?)
M[,6^RG:?[1X<'&3_WO_J2WMGG^JYI80XN*.3X; LU>_1(0LT-8<(LPI%)Y)G
MX*;S-PDQ>.^U7L@727T.TRY22R+TY2=HH'G5X0F<FF?1T?')V=LWX R='4<G
MQ__OE^/3L^C=>_".CF_S5OV L/Z$$CK7Q(B_..N'])X+M5ZC"+I?X8!APC5=
MFR,OKB<!1AVT>L"3.%>"Y,8&-)E#J^NQEG]8U>D<6Z8;(N -F2E+W\U3I1,B
M,]FMO3833*C3Z34D=")4X=^X+.M)<+LKS N7AG38W%S'MAV"8(2/VU;LJJ@N
MUW>"O6Y%#_;7K*AIY/C\[EKU?2&4\/4)CYWM+>H)@-:5Y;?V^/;S<DA.>&O_
M>_B?![N NV-?0%BTT)[<R&=4OJ2HIQ/ET\M/6?G)M4O_L-=_;WSK;WAUW.4K
M>U)QVZW\8)=P_SXL(=I#3/PU7+\\U01X0VMXL^#2VO5:UP_Y[I;PX#XLX6UV
MH:2WJ?U,R4T2@R7NS,S16^];@$AN8^[>IHGV_HAV^-/1B<?:36Q[?)K>2!H.
M)^U%PT;Q_0FZWM)8>'RQQQ<;S8OE"]B&1?NWK_)%<J[^O;WUV_+\JZBIT^XG
M7LQU]_GR]U>^I80=NR]P_Z=)(>J6%"9_+;'"9[O;R]^_ZCUUI_?4G>!37_RQ
MIW[F\^.NPR6:;=;%IIH>F0PRB\,5"[F-3^F6)J9(W3VDUW+1Z%._<<@J";)B
MN@URQR.'&O,&'I@.X6C;PGF2^@\"8>40"=Q4 C/]_AG.T*^O![(K?WLS84"$
M[DA>OOWZQ<ZKT[?_>'=X]LO)<?3^3?3#^Y]>'Y_ YWO#,:A1O] -,W_WX%UT
M7.-M>8%]2L$80H:.MF_\WOB?SS$+8Y9UNN/+O 55G-Y@@D\-L2M"X&U/)/Z\
M8N1O=_;O%J1Z_<H_]#6^T98)+>:G;9N_]'12NO[SSN=?>T)?@WWQZ>I[W2S>
ML@[F%NGE+X2A^"1,P"-&P1&Y,$;A^'<B9(UV-@^E%%'__?MK<0O-9Q:E+S@G
MMS0%#MLV04J6Q[WSU]P[?QAG-;J=?SOVH3\H[W>S/.]7F%& '0(^OVZJC-Q/
MJR42-3!GZ%1%W^S&!]O;E%"BREI\FJ)*&/E1HUO,<$":V2&P\NXBAX$Z!-Z6
M87 D,^#24]C"19D#K'.T8Z_5>=Y@B@6O^*U:U652C+_*9YT4_PR_G1=7T<]8
M7(F-+WV&GM&^$PON0D:_<$:/4ILW49H4Z8JYH:8)EG81);D?TN(JTH$V?Y^0
M+KFFZ'H$.2U"<#V]RY)6/[&USXFMD!3":NQLOGB!^J16<UFB;^"#I9*%?YS_
M/WO^M[<W=T'K^TNP<[#]N 9?; U@_C?W>FNP^[@/ON :P/QO'O368.]Q#;[@
M&L#\_]_. CS;7[< X[-8WLXBU:1U=>GP3G)#M*FRW+::20-&52C#7Z]^5W6:
M-X9=J>E /,#BJ88-HD=3YJ[%-V#*[#SJCSNW978?;9D[MV4>S]&[MV7V']?@
M;FV9Y_?,E@D1$#\:%G^F+'T Z;!H,K$&O]D_V-K>?ISDSS7);S4JSYWM;_8>
M)_ES3O*)6A9):G@$?ZH:XOT[;:M"V;JS;PZV8=:CC662$])0Q]Y- >MPQ>[C
MBMQR16@)3KH3#&YJ4J=SJOHKE0+G= *K@HN")U7_\J7YR>/*?*Z5.6[2N4J8
M#-9?A^W!A1B]^; N(?6>^C$<5=@-A*$6E$C,>@27HWT[1I"GAK:5$ZA3^*_*
M3"\0;/J!+4P:)BU(54W=R<)<V<R<BGS!<'TB(/*T6M4Y]BD$"VS\.4B>%*9'
MM-&O4KH!9!5U=-%)8W-! %7?,)'MLL@QY4S]KL$.\C_%^PIU0:;44I22L!>,
M9#JH@J!IJC2G'*6R^YQXFPJ4C&5=P09OKWB-D2_]:G"J4(I>_WIXA(GKS=4R
MVD"?;A)[D< -S-WTC\V[F0!= -' L)X=3- "P 7.ZN0R*0(2W2D<;JOE2SPN
M!FE:[CNHZ,FTRJ[@/_-V4?S]_P-02P,$%     @ B8;&5B*6,%UO#   3"@
M !X   !E>&AI8FET.3DQ+7!R97-S<F5L96%S96IU;BYH=&W=6FMSTT@6_;Z_
MHB?L0E)E^9$X"0X,5=F$U+ PD V98N?35DMJ68TEM::[9>/Y]7ON;<EV$F>
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MN_[Y*F3=/1H=[XG#\5$T/![O?P$9L^P+RQB*JE2A-^;$.^%LIU$[S[+6TGP
M:AE5J<.GEI):OZ^\+!V$W]GQ+_Z>_0=02P,$%     @ B8;&5ILRU#%I#
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M#A*JMO=_UWX56OV&KV3Y>]WG_P-02P,$%     @ B8;&5E2<!H)6(0  )MH
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MUA%ENB3[YCGXW?5H)+ )T95FP6'[K[)47'SY(/NIW/L8X!LZV3<P<J($:?\
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M47=X/NWTV^IY_[T/IL9-Y[:I?)4:AJ8X<D.4M88.YH4IBV:#R"(Q+,TTP+8
M*Z-R8(A_+1L7WT9U6V$78/*3HVY?.#DZ[IWTA>.SD].S9K?_/'F[WQ- +/5!
M]@BR*O1.!%G?<=X(O?="_X^CYSGE@AC-16CSL(]SEL'S?&8THJU< ]I<0N@*
M$1V'42+L9-_!I?$]&B<"O<:8(7],G3=[0K:LK8%Y"_+OF!F;]_AP^!KZ<>(,
M@"/2X-<2F+/.L/,58&JYNDY$5ZN#O)0=7314VQ9-JM1E8JBR0QN5@S\G 164
M*@L</S/!N:&!]-V#?B=TX,481DVZ\.37HB14O3=?'54UJ&XZ8MVIFZ+F2HYH
MNL04+:51;VA$,Q39K1S\U>Z=-(7C/YHGG>;AT5F_?=C\>%H5VMW#VL:4]4/E
MZ\[1#;$3AG\N9C.\"R06XC&UT=%V!"\0O"06[$OPEVGTYIFICA_$).W #B/0
M.RS+<)J (#X,)T$2S0Y#IRRE,?.!P8:$CJ/P&OOYU<0S,-71S5=9,H&)0#0[
MKJF(6J.NB*9CR*)NNY(A6ZKJ6A;H?.J3*8F6XZ7/DX,8YH4P$L+DDD;"<!)Y
ML>/92!3(4EZ12C;EG)<4C-$V#\9\IV[3&,^Z@$X6LE'&-QBT699*2^ )QZLI
M2&+_/:&@DK8BJ-Y[/H7>+6",ERAT>(P?! JTO_3A'7CV2>U^.,-X_;37:D\[
M,&YWU $!U)&ZK<YBC%_I#OVKWH?/(*C:ZD7+EB[Z':77;VJ=87,*:U3.;S]I
M\"=U9&/ZL=\L9W@,"A"7&I:HZYCAL8DBDKHDBX (JNF:I:MU&^/4LJC6ZPUE
MK=1*J?B50)<)M$]NVFE4WV9R\I5:-Z;6A7QDO:X;NJ:88KVN:2+0IRU:FM80
M+=G13,TV[895KQR8ABAIFJH8R[GF(KF^&,&ZI)H9W>X<AJ.1%V.]D8 R4.!D
M]>9%L>2:I;5/3H6CT=@/9V!SE)E'Z(:U-\MXW"0_47]\)'K#7KZWP-J.Z=]T
MG(C&<?K/1YB _"*%U3?9\[.OE@G:D*)JU.IU4:-8_."ZDFBY<L.$/TVIZY4#
M556$H\#V B\!I_)W_]I9ZQQO@W\8A0C?ZDS\-(2K_'J$*WV57##H $9BW34:
MHN8X#=&0&HY(++#C3)VJ=5.I')Q.//#L9&FM3?=*KMLAUT/XV(OZX?37BYHT
M;[]:==,Q; T]#@VS@+8E6E0FHJ-;DNE22R4*J1SD$G:16*L_CEI_.D)DL9Y>
M=!R%UQXKG?[5J%'Z:LB:*3<,4U0,VQ2UAN&*!G5L46T0JVYHBFLH5N7@L/E\
M9.9/1X7'89P0_\(;\T#SKT2#$LSIJZ49MNH:MDB)245-52V1$+<N6FI=,RAU
M',,RP,<%.*YW;Y]SYF+G>U8&(QE%E/R2I#/X:IB +X/:HF2JX+&HC;H(CHHA
MU@FQ5*51UQU5K1P8NK%(.&^^9YW3Q] F_O%E&+SD,.TWZ17]*S$U %W#%C7-
M!BM'DS614$<1)5?6==NR%$,'*T=1--&L2](+R0W-\^C__LU0Y,9^+"34IV-$
MM1 P7%<Q0^1/,-HD$&!,("R'/K<,ZYKEO0\C '^:/8Y8QA.^$JZE8&$N9HR#
M 76$&,TEP2=Q5JOSF!4.)W'BN;-M+O'PDMI70G))!3(>1^$8.@27T IO!(OZ
MX127B \1$((A_B6XGH^(]&+ :D(#!Y:>A+#ZT<1/2$##2>S/A)@D7NS.V)OI
M"Z$%*R19SA ?%%+Q$^@'P!K,LF=NZ,/@^![FDST,<,9[/V%J4:Z9ZM-G%DV]
M9C2^=V;1I^XR;+8;(_Z."NM+Y"5 WAA?GP1IV#E>+GFPPM"W"-!J ASS(I5:
MFLUI^:-NOSWK#"]&W=L!S,\9=90CK=<ZO^E^:=]<M$ZN+F"L3G]I?Q',Z5SN
M#-NS[NA<[;6.I*YR?GO>'VC=X9%\/GQ_U?UPXL.Z;D 1+N<>-<,RJ>LV1%73
M03.:C@I*4=)$2JEEZ;I<EXA3.?CW;V9#T_:?-O.XGH#S729;D< IJ<'LB[0F
MC"=1/$'A".+U9 +B3%/T5%"BA#RE]@1>]&@L-.U$V)$;PN'[$P$HN08-%Y3/
M'1M%C#LVBJS<"O* IJ_"9;5P.0U]SP;<!8,.*%N<Z:MD^4;),EN2+!:5ZU2S
M092X4D/4W+HL&@T=OCI$;Q!#M337W;IDV9I0F9.8,$II;%FBR!H19:4@5(YN
MN#E;%BD:& RLY8J<ZZL\>0;RY#BB:*C@-E>VF0C-\JCGNNAGO\J5;Y(KTI)<
M4>MNW=&I(9*Z71<UJ2&)IDP<4<7 L"81:KO2SRM7@-1$NT!K]UHMLN:(RH[U
M9C,IP]N^RID7(6?:<3RAT:NT>3IIHRQ+&[FN:IKABHV&+8N *$LT5<<474>7
M&V9=4:AFO4J;N;11J:CMV)M)F[3M(RO)?GSHKN "\E@:C:A3@@FT8!$WF4G@
M-+8&</@90VFJ65,D]5&QM+N?:5+]R2-T<J,F&8^=T+8GRR"K_9"-"IPXMED*
MWL<3R_@&7/M2L'T2%P+/#[0C7BX0(L+2-:>SD17Z._%#"HI_#@ATT_V"C IH
MID) E$XO/?AE+F_W'E)/GLI/E*ZP;B$&)]T1LA4\]XKL[QD0XYIL)BL6X[\7
M;"F>#VVM^Z'K=UH75YW6G\-NZTK&_0[=V[;>&77DB]:9? $67^_+T8*E./;
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MZ:P E:D8*ZF> HY&!,-L=D31P0E1 Z:?69)W#B8$$N#ETAMS:N+TG^:"$"Q
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M,P)+ GVN((WG+,4N5OHU=P1H"BFA<I"#*=-4I&8Q#J:D>- $V#7S?&TO B,
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MV_G.-$S:@.V'FF 5)^MO?@; 3UGOINDUHVX^>6F:4C/-QY71W3G91LW0-JO
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M!O9#K-SY.,..W$'^0J2DH'5Q.N\0UINT3MA7L-NP8+AB^^]G:^@$^]U>C?X
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M"Y&SX],S&QDSF:AAF97E0)8_CSX3^Z-_TM?" *]"7RCQZBK[,3'W&@H0*B]
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MC/Z0 !S) /@1A(P&Y>Q?Z[ZNJ9&Q27&%TUL"]4JDGH'JE5@[S"PT4=IBD'@
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MJSH\:+1J]:U_.W/E/*RZO8L(Y:*[ZJ'?-MF%9A%3\EQ+3J3@ELB(*!G/*1'
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M:6YG86=R92YH=&U02P$"% ,4    " ")AL96LPN^N'M%  #H]0$ '@
M        @ $WI@  97AH:6)I=#,Q+7-E<FEE<V9P<F5F97)R960N:'1M4$L!
M A0#%     @ B8;&5@UGSW:>3P  #A0" !X              ( ![NL  &5X
M:&EB:70T,RUW87)R86YT86=E;F-Y86=R+FAT;5!+ 0(4 Q0    ( (F&QE8B
MEC!=;PP  $PH   >              "  <@[ 0!E>&AI8FET.3DQ+7!R97-S
M<F5L96%S96IU;BYH=&U02P$"% ,4    " ")AL96FS+4,6D,   *+   '@
M            @ %S2 $ 97AH:6)I=#DY,BUC;&]S:6YG<')E<W-R96PN:'1M
M4$L! A0#%     @ B8;&5E2<!H)6(0  )MH  !$              ( !&%4!
M &MP<G@M,C R,S V,#(N:'1M4$L! A0#%     @ B8;&5C^ 45%N @  ?0<
M !$              ( !G78! &MP<G@M,C R,S V,#(N>'-D4$L! A0#%
M  @ B8;&5D=M46+N"@  ^F0  !4              ( !.GD! &MP<G@M,C R
M,S V,#)?;&%B+GAM;%!+ 0(4 Q0    ( (F&QE8>*^C2#0<  !<U   5
M          "  5N$ 0!K<')X+3(P,C,P-C R7W!R92YX;6Q02P4&      D
,"0"  @  FXL!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
